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Human immunodeficiency virus type 1 (HIV-1), the virus that causes acquired immune 
deficiency syndrome (AIDS), is one of the world’s most serious health and development 
challenges. Worldwide there are approximately 36.7 million people living with HIV, and 
tens of millions have died of AIDS-related causes since the beginning of the epidemic. 
Treatment of HIV-1 infection with combinations of antiretroviral drugs has significantly 
reduced the death rate and improved the quality of life of HIV-1 infected individuals. 
Despite over thirty years of HIV-1 research, however, both a cure and a vaccine remain 
elusive. Complete eradication of HIV-1 by antiretroviral drugs is prevented by the 
persistence of rare, long-lived, latently infected cells. These cells, called the latent 
reservoir, are thought to resist immune clearance and viral cytopathic effects by harboring 
a transcriptionally quiescent integrated HIV-1 provirus. As a result, interruption of 
suppressive therapy almost inevitably results in rapid viral rebound, which originates from 
these latently infected cells and prevents HIV-1 cure. It is thought that establishing the 
reservoir requires intact retroviral integration into the host cell genome and subsequent 
transcriptional silencing of the integrated provirus. These are rare events and these cells 
have no known distinguishing surface markers, which has made it difficult to define the 
precise cellular and molecular nature of the reservoir. The long half-life of the latent 
reservoir has been attributed to a stable pool of long-lived latently infected CD4+ T cells. 
An alternative explanation, consistent with the frequent occurrence of monotypic viral 
sequences, is that infected latent cells are maintained in part by cell proliferation. T cell 
division and productive HIV-1 transcription are mediated by shared metabolic and 
transcriptional pathways, and productive HIV-1 infection typically leads to CD4+ T cell 
death. Thus, how infected cells survive while dividing is unknown. I focused my thesis on 
characterizing this latent reservoir in virally suppressed, HIV-1 infected individuals and 
examining the mechanisms of HIV-1 latency. 
In the first part of this thesis, using a novel single-cell, high throughput integration 
site sequencing method, I demonstrate that HIV-1 infected cells are capable of cell 
division, but that the great majority of the largest expanded clones contain defective 
proviruses which cannot contribute to the replication competent rebound virus. In the 
second part of this thesis, using an assay to qualitatively and quantitatively characterize 
the latent reservoir, I suggest that the replication competent latent reservoir may, in fact, 
be maintained in part by rare cell division events. And finally, I developed a novel isolation 
strategy which allowed single cell characterization of recently reactivated latent cells. I 
was able to obtain reactivated latent T cells that produced intact, replication competent 
HIV-1. By sequencing the T cell receptors, I prove that these isolated latent cells are 
expanded T cell clones. Single cell gene expression analysis revealed that latent cells 
share a specific gene profile that prominently includes genes implicated in silencing the 
virus, T cell exhaustion markers, and genes that may aid in identification of specific CD4+ 
T cell subsets prone to latent infection. Together, the data supports a model for latency 
whereby infected T cells turn on a gene expression program that suppresses viral 
replication during cell division thereby preventing activation of the cell death pathways 
that are normally triggered by HIV-1 infection. 
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History of Global HIV Epidemic 
Acquired Immune Deficiency Syndrome (AIDS) was first identified in 1981 when 
young homosexual men began dying of opportunistic infections and rare malignancies. A 
retrovirus named Human Immunodeficiency Virus type 1 (HIV-1) was determined to be 
the causative agent of AIDS, now one of the worst infectious disease epidemics in recent 
human history. HIV-1 is primarily a sexually transmitted disease, but can be transmitted 
also through percutaneous, perinatal and intravenous routes (Maartens et al., 2014). 
There are an estimated 36.7 million people currently infected worldwide, and 25 million 
HIV/AIDS related deaths thus far (UNAIDS, 2017). The greatest disease burden is found 
in developing countries, with young adults in sub-Saharan Africa representing the highest 
disease prevalence worldwide (Figure 1.1) (Collaborators, 2016). 
Figure 1.1 Worldwide prevalence of HIV. 
Adapted from 2016 Global  
HIV and AIDS Statistics. 
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The spread of infection and illness caused by HIV-1 infection have been mitigated by the 
administration of antiretroviral drug cocktails, either for prevention or treatment (Arts and 
Hazuda, 2012). Therapy, although not universally available, has improved survival rates 
and lengthened disease-free state. These virologically suppressed HIV-1 infected 
individuals, however, still have shorter life expectancy and slightly worse health outcomes 
than their uninfected counterparts (Hunt, 2014). Additionally, efforts to discover a cure or 
an effective vaccine have been largely unsuccessful. As a result, HIV infection and AIDS 
related illnesses are positioned to continue their attack on the global population, 
especially under-resourced communities, for the coming decades. 
HIV-1 life cycle 
HIV-1 is a human-tropic, single-stranded, positive sense, enveloped, RNA virus in 
the retroviridae family. The virus envelope protein interacts with cell surface receptors 
CD4 (Maddon et al., 1986; McDougal et al., 1986) and CXCR4 or CCR5 (Berger et al., 
1998) to enter its target cells – primarily CD4+ T cells of the immune system. Viral entry 
occurs upon membrane fusion (Wilen et al., 2012), followed by reverse transcription of 
the RNA genome into double stranded DNA by the virally encoded Reverse Transcriptase 
enzyme (Hu and Hughes, 2012). HIV-1 reverse transcription is error-prone, leading to an 
extremely high mutation rate which results in the impressive diversity of HIV-1 genomes, 
even within a single individual. These mutations may confer resistance, allowing HIV-1 to 
evade individual treatment modalities and vaccines (Abram et al., 2010; Keele et al., 
2008). The resulting double stranded DNA is imported into the nuclease where the viral 
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protein integrase and host co-factors mediate host genome cutting, viral DNA insertion 
and DNA repair around the inserted provirus (Craigie and Bushman, 2012). After 
successful integration, the cell is permanently infected. The fate of this provirus can take 
two forms: first, the virus can be targeted by host transcription machinery for the 
production of HIV-1 RNA. These RNAs are either translated into viral proteins to 
assemble new virions, or full length viral RNAs are packaged into new virus particles, 
which release from the host cell membrane to begin the replication cycle again. Second, 
and much less frequently, the virus can become latent and is not transcribed, allowing the 
cell to survive and avoid detection by the immune system (Finzi et al., 1997). This pool of 
latently infected cells, termed the latent reservoir, is long lived (Finzi et al., 1999), 
insensitive to antiretroviral therapy (Chun et al., 1997b; Dinoso et al., 2009), and is the 
source of viral rebound after therapy cessation (Joos et al., 2008). Thus, the persistence 
of latently infected cells is the major barrier to HIV-1 cure. 
Immune response to HIV-1 and broadly neutralizing antibodies 
Most HIV-1 infections occur via the mucosal route during sexual contact, though it 
is unclear whether HIV-1 is transmitted as a free or a cell-associated virus (Pope and 
Haase, 2003). The mechanism used by HIV-1 to cross the mucosal epithelium during 
transmission is unknown, but it’s thought that virus reaches the mucosal epithelium by 
either vesicular transport through epithelial cells or by making contact with dendritic 
processes of intraepithelial dendritic cells. Transmission frequency increases if the genital 
mucosa is damaged by physical trauma or co-existing infection, which allows 
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transmission via the epithelium to occur more easily (Galvin and Cohen, 2004). Viral 
transmission across the mucosal barrier seems to be a rare event, however, as studies 
of the first detectable viremia suggest that infection is initiated by a single infectious virus 
called the transmitted-founder (TF) virus (Keele et al., 2008; Parrish et al., 2013). 
Homogeneity of the TF virus is indicative of early infection events originating from a single 
virus and focused to a close group of mucosal resident CD4+ cells, with early viremia 
enhanced by recruitment of non-tissue resident susceptible CD4+ T cells to the initial site 
of infection. Peak viremia occurs around 28 days post exposure and correlates with a 
dramatic HIV-1 induced loss of CD4+ T cells from tissues and the periphery (Brenchley 
et al., 2004; Keele et al., 2008). Following peak viremia, plasma levels of HIV-1 RNA 
gradually decrease for a period of up to 20 weeks until viral set-point is reached. Without 
therapeutic intervention, this viral set-point represents the homeostasis between the anti-
viral activity of the immune system and the virus’ ability to evade immune response. In 
part, the ability of the immune system to manage viral infection lies in CD4+ T cell function. 
Actively infected CD4+ T cells have a measured half-life of approximately one day, 
demonstrating the vulnerability of these cells in the context of HIV-1 infection (Markowitz 
et al., 2003). HIV-1-specific CD4+ T cells are required for helping B cells in the lymphoid 
germinal centers make high affinity antibodies. While the immune system mounts a 
complex and multi-tiered response against HIV-1, for the purposes of this thesis 
introduction, I will now focus only on the development of antibody responses. 
 Antibodies develop early in infection and are directed to HIV-1 Envelope (Env), a 
sparsely expressed protein on the surface of virions and cells actively infected by the 
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virus. This protein serves as the target for neutralizing humoral immune responses since 
it is the only viral protein expressed on the surface of the virus. Gp120 and gp41 comprise 
one HIV Env monomer, which come together to form a functional Env protein trimer (Ward 
and Wilson, 2015). The trimer is highly unstable and antibodies arise against gp41 as 
early as 2 weeks after infection and against gp120 3-4 weeks later (Binley et al., 1996; 
Tomaras et al., 2008). Despite their abundance, these antibodies do not detectably 
control viremia or exert evolutionary pressure on the diversifying Envelope protein (Keele 
et al., 2008). Months later, neutralizing antibodies arise that target autologous virus. 
Neutralizing antibodies have 2 main functions: 1) they disrupt viral replication by binding 
cell-free virus and prevent the virion from infecting new target cells and 2) they bind to 
Env expressed on the cell surface and via the FC region, mediate antibody-dependent 
cellular cytotoxicity. These autologous neutralizing antibodies drive virus neutralization 
escape (Escolano et al., 2017). This was revealed during studies of antibody and virus 
co-evolution which demonstrated that earlier circulating viruses are more sensitive to 
current serum antibodies than concurrent circulating viruses (Doria-Rose et al., 2014; 
Liao et al., 2013). Thus, it seems that autologous neutralizing antibodies drive evolution 
of the virus Envelope, which in turn drives evolution of the antibody response in the 
germinal center reaction (Figure 1.2). Viral escape occurs when favorable mutations arise 
during the random reverse transcriptase-mediated mutagenesis of HIV-1. These 
mutations take the form of amino acid deletions, substitutions or insertions, particularly 
via the shielding of functionally constrained regions by the addition or subtraction of 




Figure 1.2 The evolution of the HIV-1 envelope on the virus drives the 
diversification of the antibody response.  
 
Rarely, neutralizing antibodies in a single individual evolve to increase in breadth 
and potency and develop the ability to neutralize heterologous viruses. The mechanism 
for the development of broadly neutralizing antibodies (bNAbs) is widely studied, and 
while there is not a consensus, it seems that persistent antigen exposure is important 
such that 1) length of untreated infection, 2) viral load and 3) viral diversity, all contribute 
to broadly neutralizing antibody development in vivo (Gray et al., 2011; Rusert et al., 
2016). However, the number of people who develop broad and potent antibodies is much 
fewer than the number of people who experience persistent antigen exposure, which 
suggests that there are additional, currently undiscovered factors (perhaps host-specific) 
which contribute to bNAb development.  
Through techniques pioneered by the Nussenzweig laboratory, a new, extremely 
potent and broad generation of bNAbs have been cloned from single B cells obtained 
from individuals with highly neutralizing serum in the last 10 years (Klein et al., 2013). The 
study of these antibodies has led to the discovery of vulnerable epitopes on the Envelope 
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spike protein, novel therapeutic and vaccine strategies, and important developments in 
understanding cellular mediated control of HIV-1 infection in non-human primates 
(Escolano et al., 2017). 
CD4+ T cell dynamics in HIV-1 infection 
CD4+ T cell responses play a necessary role in effective cellular and humoral 
antiviral immune responses. In response to cognate antigen presented by dendritic cells, 
naïve CD4+ T cells proliferate and differentiate into effector cells. Depending on the 
context of the stimulus, naïve CD4+ T cells may differentiate into one of several lineages 
of T helper (Th) cells, including Th1, Th2, Th17, and induced Treg, as defined by their 
pattern of cytokine production and function (Sallusto, 2016; Zhu et al., 2010). Discovery 
of these subsets has revealed phenotypic hallmarks of each lineage, including the 
definition of molecular mechanisms (usually one or multiple transcription factors) that 
dictate differentiation and function. However, due to the complexity of immune responses 
in vivo, the relevant function of these subsets has yet to be fully understood in the context 
of the human immune system (Swain et al., 2012). Upon resolution of the immune 
response, the majority of the effector cells die, leaving behind only a small fraction of the 
clone in a pool of memory cells with diverse phenotypic and functional properties and 
gene expression profiles which are poised to mount a faster secondary immune response 
when the host encounters the same antigen (Mahnke et al., 2013). 
Since HIV primarily infects and kills CD4+ T cells, efforts have focused on 
understanding HIV-1-specific CD4+ T cell responses. Progress has been hindered by a 
8 
number of considerable challenges inherent in studying ex vivo isolated CD4+ T cells and 
their role in HIV-1 infection. These include: 1) the lack of necessary tools (MHC Class II 
tetramers are much laborious to produce than MHC Class I tetramers, for example), 2) 
the short lifespan of HIV-specific CD4+ T cells, as they are thought to be preferential 
targets of HIV (Douek et al., 2002), and 3) perhaps most importantly for ex vivo human 
studies, the indirect experimental readouts of CD4+ T cell function: CD4+ T cells act 
primarily by helping other immune cell subsets within complex tissue architecture. 
Chronic infection like HIV-1 can lead to dysfunction of responding immune cells, 
including CD4+ T cells. During early, acute HIV-1 infection, CD4+ T cells produce the 
hallmark Th1 cytokine IFNγ and T cell clones specific to several HIV-1 peptides can be 
readily identified (Oxenius et al., 2001). These early robust Th1 responses decrease as 
infection progresses, and within a few weeks, the detectable HIV-1 specific CD4 response 
is dramatically decreased.  The HIV-1 specific response by CD4+ T cells does not return 
to initial levels, even after sustained antiretroviral therapy. This loss of specific CD4+ T 
cells could be explained by favored infection of HIV-1 specific CD4+ T cells (Douek et al., 
2002), bystander cell death induced by HIV infection (Doitsh and Greene, 2016) or 
persistent CD4+ T cell fatigue. There is also evidence that early initiation of therapy may 
mitigate HIV-specific CD4+ T cell dysfunction (Cellerai et al., 2011), which could imply 
that the initial insult of chronic HIV infection affects lasting change to the immune system’s 
overall function. 
Understanding CD4+ T cell responses during HIV infection is tightly linked to 
understanding the establishment of the latent reservoir. The latent reservoir is established 
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very early during infection (Archin et al., 2012; Chun et al., 1998), and because of its long 
half-life of 44 months (Crooks et al., 2015; Finzi et al., 1999) it is the main impediment to 
curing HIV-1 infection (Siliciano and Greene, 2011). Resting CD4+ T cells have a longer 
half-life in vivo than effector cells but resting CD4+ T cells are relatively resistant to 
infection compared to activated effector cells. Since activated CD4+ T cells are prime 
targets for HIV-1 infection for a number of reasons (CCR5, the co-receptor for HIV-1 entry, 
is upregulated upon CD4+ T cell activation, NF-κB and other transcription factors required 
for HIV-1 RNA transcription are present in activated cells, and finally SAMHD1, a protein 
that disrupts reverse transcriptase, is highly expressed in resting cells (Murray et al., 
2016)) but die quickly, how is the latent reservoir established and maintained in the 
overwhelming majority of HIV-1 infected individuals? The predominating hypothesis 
posits that a few activated CD4+ T cells become infected during the cellular transition to 
a long-lived resting memory state that does not support high level viral gene transcription. 
These events occurring in concert to support latency is a rare occurrence, which 
corresponds with the relative rarity of latent cells in vivo (~1 per million CD4+ T cells) 
(Crooks et al., 2015; Finzi et al., 1999).  
It is thought that these latent cells do not transcribe viral RNAs or make viral 
proteins, and thus avoid detection by the immune system and are not eliminated by 
antiretroviral therapy. If it’s assumed that latent cells are simply long-lived memory CD4+ 
T cells harboring a copy of HIV-1 DNA integrated somewhere in their genome, it’s not 
unexpected that these cells might have a long half-life in vivo. This model attempts to 
explain HIV-1 latency in the framework of the normal physiology of immunologic CD4+ T 
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cell memory. It is consistent with the idea that antiretroviral therapy may merely reveal 
latency, rather than a hypothesis which requires the virus to harbor some special 
mechanism for latent infection. 
Establishment of the latent reservoir and HIV integration 
For the purposes of this thesis, I will define HIV latency as the reversibly 
nonproductive state of infection of individual host cells with a stable, intact integrated form 
of the viral genome. Although the latent reservoir remains to be completely described, it 
is thought that establishing the reservoir requires intact retroviral integration into the 
genome and subsequent transcriptional silencing (Siliciano and Greene, 2011). Latency 
may be enforced by silencing epigenetic modifications of the integrated provirus (Wang 
et al., 2007) and the virus persists essentially as genetic information, being protected with 
the host genome in the nucleus of the cell as the cell carries out its normal function. 
The first essential step in establishment of the latent reservoir is the integration of 
the provirus into the genome. After reverse transcription, the double stranded viral DNA 
forms a complex with host and viral proteins called the preintegration complex (PIC). The 
PIC is a large complex which is imported into the nucleus via a largely unknown 
mechanism, but since HIV-1 can infect non-dividing cells, import of the PIC into the 
nucleus is likely an active process. Once in the nucleus, the PIC accesses the host 
chromosomes. Viral protein integrase is an integral part of the PIC and is responsible for 
cutting the DNA and joining the host and viral genomes. Many different studies provide 
evidence to show that HIV-1 preferentially integrates into a subset of transcriptionally 
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active genes of the host cell genome (Craigie and Bushman, 2012). More recently, it was 
demonstrated that this preference may be due to nuclear topology (Marini et al., 2015). 
HIV-1 integration seems to occur in the outer shell of the nucleus in close proximity to the 
nuclear pore. This region contains a series of number of host genes, which are 
preferentially targeted by the virus, and characterized by the presence of active 
transcription chromatin marks before viral infection. Additional evidence suggests that 
HIV integration into the genome is known to favor the introns of expressed genes (Han et 
al., 2004), some of which, like BACH2 and MKL2 carry multiple independent HIV-1 
integrations in different individuals and are considered hotspots for integration (Maldarelli 
et al., 2014; Wagner et al., 2014). Functional viral integrase, and the presence of the 
cellular Nup153 and LEDGF/p75 integration cofactors are indispensable for the 
perinuclear integration site selection of the virus (Marini et al., 2015). Thus, virally 
encoded and host proteins coordinate to direct HIV-1 to specific regions of accessible 
chromatin. 
Whether or not the genomic location of the integration impacts on latency is 
debated (Jordan et al., 2003; Jordan et al., 2001). Several mechanisms could silence HIV 
gene expression and replication. These include but are not limited to: transcriptional 
interference (Lenasi et al., 2008), problems with or limitations to RNA processing and 
transport (Lassen et al., 2006), epigenetic silencing such as changes in DNA methylation 
(Kauder et al., 2009), and the presence of repressive transcription factors, or the absence 
of necessary positive transcription factors (Van Lint et al., 2013). These mechanisms 
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could contribute individually and/or in concert to the transcriptional silencing of HIV and 
permit infected host cell survival.  
 
Measuring the latent reservoir 
The HIV-1 latent reservoir has been difficult to define for two major reasons: first, 
the majority of integrated proviruses are not replication competent and do not contribute 
to viral rebound after treatment cessation but do confound direct measurements of viral 
nucleic acids by overestimating the number of latent cells. Second, a complete 
understanding of viral reactivation is lacking and thus induction from latency is 
incomplete, which prevents accurate measurement of intact latent viruses.  
 The gold standard for latent reservoir quantitation is the Quantitative Viral 
Outgrowth Assay (QVOA) (Laird et al., 2013). Blood or leukopheresis product is obtained 
from HIV-1-infected individuals, and CD4+ T cells are isolated. The CD4+ T cells are 
plated in limiting dilution to allow quantification and are stimulated with PHA or other 
latency reversing agents (LRAs) and irradiated peripheral blood mononuclear cells 
(PBMC) from a non-infected donor to stimulate viral outgrowth. The next day, target cells 
(either CD8 depleted lymphoblasts or an HIV-1 permissive cell line) are added as a source 
for amplification of the released virus. After several weeks, wells that contain replication 
competent HIV-1 are detected by ELISA measuring supernatant HIV-1 p24 gag protein. 
QVOA is the only assay which detects solely replication competent virus. However, the 
drawbacks of this assay are significant – primarily that the assay does not detect all 
replication competent virus because reactivation of the latent reservoir is incomplete with 
13 
current modalities. It is also time-consuming, resource-intensive, and requires large blood 
draws from the study participants. 
Efforts to more accurately and more quickly quantitate the latent reservoir are 
underway. The tat/rev induced limiting dilution assay (TILDA) measures inducible multiply 
spliced HIV-1 RNA (Procopio et al., 2015). Multiply spliced HIV-1 RNA is only produced 
in actively transcribing cells who harbor an intact proviral LTR and is therefore a more 
accurate predictor of the active reservoir than quantitation of genomic proviral DNA. 
Furthermore, the PCR primers used in TILDA are specific to the tat/rev region, which is 
the most commonly deleted region in defective proviruses. As one example from a treated 
individual, TILDA estimated a latent reservoir that was 48 times higher than that 
measured by QVOA and approximately 6–27 times lower than that predicted by PCR-
based assays. This demonstrates its ability to measure a larger proportion of the latent 
reservoir than QVOA while being more selective in measuring likely intact virus than 
traditional DNA PCR-based approaches (Procopio et al., 2015). 
Although QVOA is the gold standard, the assay tends to underestimate the size of 
the reservoir because some proviruses are relatively resistant to reactivation in vitro as 
revealed by near full-length genome sequencing (Ho et al., 2013). QVOA estimates the 
reservoir size in treated individuals to be, on average, 1 latent cell per million CD4+ T 
cells. Since QVOA requires proviral reactivation, recently three studies performed 
characterization of the replication competent reservoir by PCR to avoid any bias 
introduced by reactivation (Bruner et al., 2016; Hiener et al., 2017; Ho et al., 2013). These 
studies employ an unbiased single genome amplification approach to define the 
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sequence landscape of persistent proviruses. Using a near full-length viral genome PCR, 
proviruses in patient samples are amplified at limiting dilution to avoid any PCR artifacts. 
Following outer PCR amplification, inner segments of the virus are amplified and directly 
sequenced, allowing the reconstruction of the full viral genome while limiting the potential 
for PCR generated mutations. This method has defined a new subset of reservoir viruses 
which are non-induced, but genetically intact. The size of the reservoir measured by these 
full-genome sequencing methods is estimated to be 10 to 100-fold greater than that 
measured by QVOA. These experiments are time intensive and laborious but require 
many fewer cells than QVOA. Additionally, though these viruses have an intact genome, 
whether these viruses could reactivate in vivo is still undetermined. 
These results may suggest that 1) the barrier to cure may be much larger than 
originally thought, 2) our current methods are insufficient to reactivate all intact viruses, 
and 3) more efficient methods to measure the size of the reservoir are needed. 
Evidence for clones of infected cells 
CD4+ T cell death is the primary result of productive HIV-1 infection (Doitsh and 
Greene, 2016). The mechanism of CD4+ T cell depletion in vivo is not entirely understood, 
but it was thought that infected cells would die before they were able to divide because 
cell activation triggers both cell division and HIV-1 transcription (Nabel and Baltimore, 
1987; West et al., 2001; Williams and Greene, 2007). However, increasing evidence has 
begun to suggest that infected cells are able to divide in vivo. 
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Successful antiretroviral therapy reduces HIV-1 plasma viremia to below the 
detection limit of ultrasensitive clinical assays (20 copies of HIV-1 RNA/ml plasma). 
Nevertheless, very low levels of free virus can be found in the plasma. Sequencing the 
residual plasma viremia revealed persistent virus released from infected cells for months 
to years without evident sequence change (Bailey et al., 2006). Comparison of the plasma 
virus with integrated, cell associated viruses showed that occasionally some sequences 
in the plasma were identical to viruses in resting CD4+ T cells (Anderson et al., 2011). 
Despite the large diversity of HIV-1 sequenced from resting CD4+ T cells, the residual 
viremia was dominated by a homogeneous population of viruses with identical sequences 
(Bailey et al., 2006). Thus, in individuals on antiretroviral therapy, a mechanism for 
residual viremia involves persistent production of a small number of viral clones without 
evident evolution. Since new viral replication results in mutagenesis of viral sequence, 
one plausible explanation for this observation is the proliferation of infected cells carrying 
a single integrated provirus. An alternative, but less likely, explanation is that identical 
sequences could result from a burst of infectious virions which each infected unrelated 
CD4+ T cells. 
Upon antiretroviral therapy cessation, viremia rebounds from the latent reservoir. 
When it does, it appears to involve an increasing proportion of monotypic, archived HIV-
1 sequences, further suggesting the proliferation of latently infected cells (Joos et al., 
2008; Wagner et al., 2013). Based on this observation and the finding that a subset of 
cells bearing integrated HIV-1 undergoes clonal expansion in individuals receiving 
suppressive antiretroviral therapy (Maldarelli et al., 2014; Wagner et al., 2014), it has 
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been proposed that the clonally expanded cells play a critical role in maintaining the latent 
reservoir. 
This thesis describes three methods developed to study the latent reservoir from 
treated individuals at the single cell level. First, integration site sequencing was used to 
reveal clonally expanded infected cells which harbored primarily defective proviruses. 
Second, qualitative analysis of virus from single latent cells suggested that rarely, cells 
harboring replication competent virus could divide. And finally, the inability to isolate 
latently infected cells has limited the study of the HIV-1 latent reservoir. As a first step in 
this direction, I developed a method to identify and characterize single recently 
reactivated latently infected cells. 
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CHAPTER 2: 
HIV-1 INTEGRATION IN PRODUCTIVE AND LATENT INFECTION 
Integration Library Construction 
To obtain additional insights into role of clonal expansion in maintaining the 
reservoir and the regions of the genome that are favored by HIV-1 for integration, we 
developed a single cell method to identify a large number of HIV-1 integration sites from 
treated and untreated individuals, including “viremic controllers” who spontaneously 
maintain viral loads of <2000 RNA copies/ml and “typical progressors” who display viral 
loads >2000 RNA copies/ml. 
Twenty-four integration libraries were constructed from CD4+ T cells from 13 
individuals: 3 provided longitudinal samples before and after (0.1-7.2 years) initiation of 
therapy; 4 were untreated; 2 were treated; and 4 were viremic controllers (Table 2.1). 
Individuals were grouped into three categories based on viral loads and therapy: 1. 
viremic progressors were untreated individuals with viral loads higher than 2000 viral RNA 
copies/mL of plasma; 2. progressors were treated individuals whose initial viral loads 
were higher than 2000 viral RNA copies/mL before therapy; 3. controllers were individuals 
who maintain low viral loads spontaneously in the absence of therapy (less than 2000 




















1 Male 2000 6/17/09 
naïve 11/20/07 63500 291 Viremic 
naïve 11/17/08 8350 165 Viremic 
Truvada, 
Atazanavir, 








Ritonivir 2/11/14 <40 486 
Treated 
2 Female 1990 1/12/07 
naïve 2/8/05 15200 359 Viremic 
naïve 8/9/05 60000 295 Viremic 
Atripla 3/10/09 <30 560 Treated 
Atripla 4/6/10 <30 757 Treated 
Atripla 3/11/14 <40 965 Treated 
3 Male 2006 12/17/09 
naïve 8/5/09 4734 433 Viremic 
Truvada, 
Atazanavir, 
Ritonivir 11/18/10 0 616 Treated 
Truvada, 
Atazanavir, 
Ritonivir 12/23/13 <40 869 Treated 
4 Male 2011 NA 9/20/13 71857 530 Viremic 
5 Male 2003 NA 3/28/14 3210 674 Viremic 
6 Female 2000 NA 4/7/14 43650 520 Viremic 
7 Male 2006 NA 4/11/14 5340 607 Viremic 
8 Male 1996 4/22/97 
Tenofovir/ 
Emtriva, 
Nevirapine 4/22/13 <40 280 Treated 
9 Male 2011 9/19/11 
Truvada, 
Efavirenz 5/2/13 <40 440 Treated 
10 Male 2003 NA 5/27/10 49 1070 Controller 
11 Male 2002 Controller 
NA 5/08 410 518 Controller 
NA 7/10 880 565 Controller 
12 Male 1997 NA 7/23/10 505 430 Controller 
13 Male 1989 NA 7/23/10 <50 580 Controller 
Table 2.1. Clinical profile of human subjects. 
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Libraries were produced from genomic DNA by a modification of the translocation-
capture sequencing method that we refer to in this paper as integration sequencing 
(Figure 2.1) (Janovitz et al., 2013; Klein et al., 2011). 
Figure 2.1 Diagrammatic representation 
of integration library construction. 
Virus integration sites were recovered 
by semi-nested ligation-mediated PCR from 
fragmented DNA using primers specific to 
the HIV-1 3’ LTR. PCR products were 
subjected to high-throughput paired-end 
sequencing, and reads were aligned to the 
human genome. Since sonication is random, 
it produces unique linker ligation points that 
identify the specific integration events in 
each infected CD4+ T cell, which allows both single cell resolution and identification of 
expanded clones of cells with identical integrations ((Berry et al., 2012) Figure 2.1). Thus, 
integration sequencing can enumerate both the number of integration sites and the 
number of infected cells. 
Genomic DNA (CD4+ T cells, HIV+ donor)





Linker digestion and 
sequencing adapter ligation
Paired end Illumina Sequencing
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A total of 6719 unique virus integration sites were determined: 873 unique 
integrations in viremic controllers; 987 integrations in untreated progressors; and 4859 
integrations in treated progressors. 
Integrations enriched in highly expressed genes 
We analyzed the genomic location of the integration sites obtained from viremic 
controllers, untreated and treated progressors and compared our results to published 
data obtained from HIV-1 infected individuals (Brady et al., 2009; Han et al., 2004; Ho et 
al., 2013; Ikeda et al., 2007; Schroder et al., 2002; Sherrill-Mix et al., 2013; Wang et al., 
2007). In agreement with the work of others, the majority of integration sites in each group 
are genic (Figure 2.2a). Moreover, integrations are found more frequently in the introns 
of highly expressed genes, and there is a slight bias for viral orientation that leads to 
convergent transcription (Figures 2.2b-d) (Mitchell et al., 2004). Thus, the general 
features of integrations defined by our integration sequencing assay are similar to those 
obtained by others. 
Although the differences between groups were small in magnitude, they were 
significant in that treated progressors had a smaller proportion of integrations in genic 
regions (p<0.0001 and p<0.0001, respectively) and in highly expressed genes (p<0.0001 
and p<0.0001, respectively) when compared to viremic controllers and untreated 
progressors (Figure 2.2c). Conversely, the proportion of viral integrations in genes 
expressed at lower levels was increased in treated progressors compared to viremic 
controllers and untreated progressors (p= 0.002 and p<0.0001, respectively). Viremic 
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controllers and treated progressors were not significantly different from each other in 
terms of the level of expression of the genes at the sites of integration (Figure 2.2c). Thus, 
therapy is associated with a relative decrease in the number of cells with viral integrations 
in highly expressed genes. 
Figure 2.2. HIV Integration Libraries. a) Proportion of integrations that are in genic or 
intergenic regions in controllers (C), viremic (V) or treated progressors (T). b) Proportion 
of genic integrations located in introns in controllers, viremic or treated progressors c) 
Proportion of integrations in genes with high, medium or low expression. Integrations in 
genes with silent and trace expression contribute a minor proportion and were not 
included in this analysis. P-values refer to proportion of integrations in highly expressed 
genes. d) Transcriptional orientation of integrated HIV-1 relative to host gene in 
controllers, viremic or treated progressors. ns: not significant *P<0.05**P< 0.01 
***P<0.0001 using two-proportion z-test. 
Identification of clonally expanded infected cells 
Since we shear DNA ends randomly to produce our libraries, and by paired end 
sequencing can determine the precise site of both the integration and sheared end, we 
infer that identical integrations with unique sheared ends arise from clones of expanded 
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2 de novo integration sites would be identical, and thus we infer that identical integration 
sites arise from cell division of a single infected cell. Integrations can therefore be 
classified as clonally expanded (i.e. identical integrations with distinct sheared ends, 
deriving from the clonal expansion of an original unique, single integration event) or single 
integrations (i.e. unique integration site with a single sheared end). 
Clonally expanded viral integrations were present in all individuals irrespective of 
therapy or viremia. However, the proportion of clonally expanded viral integrations is 
significantly lower in viremic controllers (30%) and viremic progressors (27%) than in 
treated progressors (40%) (p<0.0001 and p<0.0001, Figure 2.3a and b). Although the 
size of individual clones varied from 2-295 cells (Figure 2.3c), the relative increase in 
clonally expanded integrations during therapy consistently translated into an increase in 
the number of infected cells that derive from expanded clones (Figure 2.3d and e). The 
percentage of cells containing clonally expanded HIV-1 integrations was similar in 
untreated progressors (78%) and controllers (79%), but it was significantly increased in 
treated progressors (90%) (p<0.0001 and p<0.0001, Figure 2.3d and e). Thus, therapy is 
associated with an increase in the frequency of clonal HIV-1 integrations and infected 
clonally expanded cells.  
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Figure 2.3 Identification of clonally expanded cells bearing integrated HIV-1. See 
also Figure S2. a) Proportion of viral integrations (Int) that are clonally expanded, as 
identified by the same integration site with multiple shears in controllers, viremic or treated 
progressors. b) Proportion of integrations (Int) that are clonally expanded in controllers, 
viremic or treated progressors; each dot represents data from an individual integration 
library. c) Graph shows the size of proliferating clones of infected cells. Plotted is the 
number of shears (X-axis) by the number of integrations (Y-axis). d) Proportion of infected 
cells deriving from clonal expansion in controllers, viremic or treated progressors. e) 
Proportion of infected cells deriving from clonal expansion in controllers, viremic or treated 































































































Figure 2.4 Comparing clonally expanded and single integrations. a) Proportion of 
clonally expanded (CE) and single (S) viral integrations in genic or intergenic regions. b) 
Proportion of clonally expanded (CE) and single (S) genic integrations; each dot 
represents data from an individual integration library. c) Proportion of clonally expanded 
and single viral integrations in introns. d) Proportion of clonally expanded (CE) and single 
(S) integrations in introns. e) Proportion of clonally expanded or single viral integrations 
in genes with high, medium or low expression. Integrations in genes with silent and trace 
expression contribute a minor proportion and were not included in this analysis. P values 
refer to proportion of integrations in highly expressed genes. f) Proportion of clonally 
expanded (CE) and single (S) integrations in highly expressed genes. 
To determine whether the position of viral integration in the genome correlates with 

















































































Both types of integrations favored genes and their introns (Figures 2.4a-d). However, the 
proportion of clonally expanded integrations in intergenic regions was greater than that of 
single integrations (Figure 2.4a and b, p<0.0001). Moreover, of the integrations in genes, 
single integrations were more likely to be found in highly expressed genes than clonal 
integrations (Figure 2.4e and f, p<0.0001). Thus, cells harboring viral integrations in 
intergenic regions and genes that are expressed at lower levels are more likely to be 
clonally expanded. 
Hotspots for virus integration 
Overlap between integrations in the genes of different individuals suggests the 
existence of hotspots for HIV-1 integration. A number of individual genes have been 
identified as preferential sites for HIV-1 integration including BACH2, MKL2, DMNT1, 
MDC1 and STAT5B (Ikeda et al., 2007; Maldarelli et al., 2014; Wagner et al., 2014). To 
identify hotspots for HIV-1 integration genome-wide, we subjected our data set to 
hot_scan analysis (Silva et al., 2014), which defines hotspots by identifying regions of 
local enrichment using scan statistics. This analysis identified 55, 85, and 247 hotspots 
for controllers, viremic and treated progressors, respectively. For example, the intron 
between exons 5 and 6 in MKL2 is a hotspot for integration in participant 11, contains an 
expanded clonal family in participant 10 and was also identified as a site of enrichment 
for integration by others (Maldarelli et al., 2014) (Figure 2.5a). 
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Figure 2.5 MKL2 hotspot characterization. a) Integrations in MKL2 from participants 
10 and 11. Gray vertical arrows indicate site of integrations. Colored horizontal lines show 
fragments of DNA spanning the point of integration through sheared end. Green: viruses 
integrated in the same orientation as gene. Red: convergent orientation. Orange: viruses 
integrated at same site with both orientations. b) HIV-1 gag was amplified from integrated 
proviruses in MKL2 from participant 10 and 11. PCR was performed using nested 
integration site-specific primers and HIV-1 gag primers. Sequences were clustered by the 
Tamura-Nei model to assess DNA sequence similarity. The scale bar represents 0.007 
substitutions per site. 
To validate our in-silico analysis and to further characterize the MKL2 hotspot, we 
sequenced the gag gene from proviruses integrated into MKL2 by amplification with 
nested genomic primers specific for MKL2 and HIV-1 gag. Sequences obtained from 
participant 10, who showed only one expanded clone are very closely related to each 
other, which is consistent with a single clonally expanded integration (Figure 2.5b). In 
contrast, sequences obtained from participant 11 are far more diverse suggesting that 
there were several different viral integrations in the MKL2 hotspot (Figure 2.5b). We 
conclude that the hotspots defined by hot_scan represent multiple distinct integration 
events in close proximity. 
Viremic progressors had the highest proportion of integration events in hotspots, 
indicating that in the case of high-level viremia there are specific genomic locations that 









Figure 2.6 Hotspots for HIV-1 integration. a) Proportion of virus integrations inside 
hotspots in controllers, viremic and treated progressors. b) Proportion of hotspots in genic 
and intergenic regions in controllers, viremic and treated progressors. c) Proportion of 
hotspots in introns in controllers, viremic and treated progressors. d) Proportion of 
hotspots in genes with high, medium or low expression. Hotspots in genes with silent and 
trace expression contribute a minor proportion and were not included in this analysis. P 
values refer to proportion of integrations in highly expressed genes. e) Percentage of total 
single and clonally expanded viral integrations inside hotspots. Enrichment of clonally 
expanded viral integrations compared to single integrations is significant, p <0.0001. ns: 








































































































favor integration (Figure 2.6a). Although the majority of all integrations fall outside of 
hotspots (Figure 2.6a), hotspot integrations resemble others in that they are preferentially 
found within genes with a preponderance of these in introns (Figure 2.6b and c). In all 
cases, hotspots are enriched in highly expressed genes, and consistent with the overall 
decrease in viral integrations in highly expressed genes during therapy, the proportion of 
hotspots in these genes also decreases (Figure 2.6d and 2.2c). Thus, the general 
characteristics of hotspots are similar to features of all integrations. 
To determine whether there is a relationship between hotspots and clonally 
expanded viral integrations we enumerated single and clonally expanded integrations in 
hotspots (Figure 2.6e). Only a small fraction (11-18%) of all single integrations were found 
in hotspots with untreated viremic progressors showing the highest level (Figure 2.6e). In 
contrast, there was a much higher proportion of clonal integrations in hotspots (30-46%) 
with the lowest proportion in treated progressors (Figure 2.6e). 
Integrations enriched near Alu repeats 
We next wondered whether a specific genomic feature could partially explain the 
enrichment of integrations in hotspots. We observed a significant enrichment of 
integrations inside Alu repeats (Figure 2.7a), and in close proximity to Alu repeats, 
irrespective of whether the integration is inside genes or in intergenic regions (Figure 
2.7b). Thus, a preference for Alu is independent of a preference for integration in genes. 
Previous studies have suggested that a preference for Alu repeats, at least in part 
reflects a preference for highly expressed genes (Schroder et al., 2002). To examine the 
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relationship between Alu repeats and transcription, we determined the distance between 
Alu repeats and the center of all genes. There was no positive correlation between the 
position of Alu and the level of transcription (Figure 2.7c). To determine whether the 
distance between integration and Alu repeats correlates with transcription, we measured 
the distance between the sites of integration and Alu repeats in all genes (Figure 2.7d). 
There was no significant difference between integration distance to Alu repeats in highly 
expressed, silent or trace level expressed genes. Therefore, the rate of transcription does 
not impact integration distance to Alu repeats and integration at these sites must be 
independent of transcription. 
Finally, the number of Alu repeats in a hotspot is directly correlated with the number 
of integration events in that hotspot (Figure 2.7e, ρ=0.86). The data suggests that HIV-1 
has a preference for integration in close proximity to sites in the genome that are enriched 
in Alu repeats and that this preference is independent of the level of transcription. 
Increase in clonally expanded infected cells during antiretroviral treatment 
The proportion of clonally expanded viral integrations is increased in treated 
progressors (Figure 2.3a (Wagner et al., 2014)). To further examine the effect of therapy 
on clonal expansion we analyzed longitudinal samples from three typical progressors 
before and during therapy (Table 2.1). We found an increase in the number of clonally 
expanded integrations throughout the treatment period of up to 7.2 years in two of the 
three individuals (Figure 2.8a, p=0.017) as well as an increase in the number of cells that 
contained clonally expanded viral integrations (Figure 2.8b). 
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Figure 2.7 Enrichment of integrations 
in Alu repeats. 
a) Integrations are enriched inside Alu
repeats. Total integrations identified 
inside Alu repeats were enumerated 
(red diamond) and compared to the 
expected value as defined by Monte 
Carlo simulation. The boxplot displays 
the variation of the number of random 
integrations identified inside Alu repeats 
in each iteration of the simulation.  b) 
Integrations are near Alu repeats in
genes and intergenic regions. Average 
distance to the nearest Alu repeat for all 
integrations inside genes or intergenic 
regions was calculated (red diamond) 
and compared to the expected distance 
as defined by Monte Carlo simulation. The boxplot displays the variation of the distance 
of random integrations from Alu repeats in genes or intergenic regions in each iteration 
of the simulation. c) Distance to Alu repeats from the center of highly, medium, low, trace 
or silently expressed genes. d) Distance to Alu repeats in highly, medium, low, trace or 
silently expressed genes. e) Positive correlation between Alu repeats and integrations 
inside hotspots. Graph shows number of Alu repeats (X axis) vs. integrations in hotspots 
(Y axis). Hotspots not containing Alu repeats were removed from this analysis. The 
scatter plot shows the linear relationship between the number of INT-motifs and 























































































Correspondingly, there was also an overall decrease over time in single integrations 
(p=0.017), with a half-life of 127 months assuming a non-linear regression model for one-
phase decay (Figure 2.8c). Thus, our data suggests that the numbers of single 
integrations decay very slowly over time, while clonally expanded integrations increase 
with time on cART. 
Figure 2.8 Clonally expanded viral integrations increase and single integrations 
decrease during therapy. Graphs show data from participant 1 (blue), 2 (red) and 3 
(green) from longitudinal time points. Time was normalized from 0 to 1 (727 days pre 
therapy to 2617 days post therapy).  Dotted line at t = 0.21 marks therapy initiation. 
Trendline was determined by linear regression model. Solid lines indicate significant 
change in proportion of events. a) Proportion of clonally expanded viral integrations (Int). 
b) Proportion of clonally expanded cells. c) Proportion of single viral integrations.
The increase in the number of clonal integrations during cART did not favor genic 
or intergenic regions (p=0.65), indicating that this effect is independent of the location of 
the integration in the genome (Figure 2.9a). In contrast, single integrations decrease 


















































2.9b, p=0.036). Thus, the fate of cells harboring single viral integrations in ART treated 
progressors differs from clonal integration. 
Figure 2.9 Single integrations decrease preferentially from genic regions during 
time on antiretroviral therapy. Graphs show data from participant 1 (blue), 2 (red) and 
3 (green) from longitudinal time points (Table S1). Time was normalized from 0 to 1 (727 
days pre therapy to 2617 days post therapy).  Dotted line at t = 0.21 marks therapy 
initiation. Trendline was determined by linear regression model. Solid lines indicate 
significant change in proportion of events; dashed lines indicate insignificant change in 
proportion of events.  a) Proportion of genic and intergenic clonally expanded viral 


































































































Moreover, the fate of single integrations is dependent on their location in the genome 
whereas the clonal integrations are not. These results suggest that cells bearing genic 
single integrations are selected against during therapy and that clonal expansion is not. 
Integrations in cancer related genes decrease over time on therapy 
In the 3 progressors who provided longitudinal samples, approximately 5% of the 
clonal integrations persisted through successive time points without selection for genic or 
intergenic regions compared to all clonal integrations (Figure 2.10a and b). Furthermore, 
of the genic integrations that persisted, there was also no selection for or against those 
in highly expressed genes (Figure 2.10c). Thus, the persistent clonal integrations are 
indistinguishable from the larger pool of clonally expanded viral integrations in terms of 
their position in the genome. 
Since clonal integrations have been associated with genes involved in malignant 
transformation (Wagner et al., 2014) we examined our entire data set for enrichment of 
integrations in cancer-associated genes (n = 743 cancer associated genes (Vogelstein et 
al., 2013; Zhao et al., 2013)). Although there was an overall enrichment among for 
integrations in cancer genes (329/4410 = 7.5%) compared to all genes in the human 
genome (743/25,660 =2.8%) (p<0.0001), this preference does not seem to be significant 
because it is similar to the overall preference for integration into highly expressed genes 
(Figure 2.10d).  Furthermore, we observed no overrepresentation of single, clonal or 
persistent integrations in cancer genes (Figure 2.10e).  Importantly, a significant decrease 
in integrations in cancer related genes was observed in longitudinal samples (Figure 2.9f) 
suggesting that these are selected against with therapy. 
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Figure 2.10. Integrations in cancer related genes decrease over time on therapy 
a) Percent viral integrations present in more than one time point (persistent integrations)
in participants 1, 2 and 3 (Table S1). b) Comparison of persistent (P) and clonally 
expanded (CE) viral integrations in genic or intergenic region. c) Proportion of persistent 
and clonally expanded viral integrations in genes with high, medium or low expression. 
Integrations in genes with silent and trace expression contribute a minor proportion and 
were not included in this analysis. P values refer to proportion of integrations in highly 
expressed genes. d) Proportion of cancer related (left) or total (right) integrations in genes 
with high, medium or low expression. e) Genes with integrations were analyzed for their 
association with cancer. Proportions of cancer-associated genes are shown for single, 
clonally expanded and persistent viral integrations. The number indicates the total 
number of genes from each category. f) Graph shows proportion of integrations in cancer-
related genes from participants 1 (blue), 2 (red) and 3 (green) from longitudinal time points 
(Table S1). Time was normalized from 0 to 1 (727 days pre therapy to 2617 days post 
therapy).  Dotted line at t = 0.21 marks therapy initiation. Trendline was determined by 
linear regression model. Solid line indicates significant change in proportion of events, 























































































Expanded clones contain defective virus 
Our method of integration sequencing captures the end of the 3’ LTR and identifies 
the genomic site of viral integration. To determine whether the viruses found in expanded 
clones are intact, we used nested integration site-specific PCR primers that were 
anchored in the host genome to amplify the 5’LTRs of 75 expanded clones from 8 
individuals. The clones selected for PCR verification varied in size from 5-200 out of 0.3-
2x106 CD4+ T cells. Of the 75 sequences obtained, 24 showed fragmented 5’LTRs 
flanked by the correct genomic site, and an additional 44 of the proviruses did not have a 
recoverable 5’ end (Figure 2.11a). The remaining 8 proviruses with intact 5’ LTRs were 
amplified in limiting dilution conditions using integration site-specific primers and HIV-1 
primers (Figure 2.11b). Three of the 8 proviruses could not be amplified; 4 had large 
deletions in Env, 1 had a frameshift mutation in pol and 1 had undergone APOBEC3G 
mediated hypermutation to produce a premature stop codon in env (Figure 2.11c). Thus, 









Figure 2.11. Large expanded clones are defective. a) Sequence analysis of 5’LTRs in 
clonally expanded integrations. Of 75 different clonally expanded integrations from 8 
individuals, 24 showed fragmented 5’ LTRs, 44 didn’t have a recoverable 5’ LTR, and 8 
contained intact 5’LTRs. b) Strategy for HIV-1 sequencing. 8 proviruses were analyzed 
for intact viral sequence. Nested genomic primers and internal HIV primers were used in 
a PCR walking strategy to amplify fragments a-e from specific clonally expanded 
integrations. PCR products were sequenced directly. c) Summary of HIV-1 sequencing 
from large expanded clones. Sequences were aligned to HXB2 and examined for 
presence of large internal deletions. Intact sequences were analyzed for G à A 
hypermutation by Los Alamos Hypermut algorithm. Non hypermutated products were 
analyzed for intact reading frames and frameshift mutations by Los Alamos HIVQC. 
Green dot: intact, non hypermutated sequence. Red dot: no PCR product recovered. Red 
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Using a novel integration sequencing method, we studied the integration profile 
of HIV-1 in viremic progressors, individuals receiving antiretroviral therapy and viremic 
controllers. We identified infected clonally expanded T cells which represented the 
majority of all integrations and increased during therapy. However, we could not recover 
intact virus from any of the 75 clones we assayed. This data indicates that the HIV-1 




QUANTITATIVE AND QUALITATIVE VIRUS CHARACTERIZATION 
Quantitative and Qualitative Viral Outgrowth Assay 
After the identification of clonally expanded infected cells, and the observation that 
the majority of the largest clones harbor defective viruses, I sought to understand the 
composition of the replication competent reservoir. To investigate the genetic and 
phenotypic complexity of the replication-competent reservoir, the quantitative viral 
outgrowth assay (QVOA) protocol was modified to increase the number of unique 
outgrowth cultures. 
Figure 3.1 Quantitative and qualitative analysis of the replication-competent 
reservoir. Diagrammatic representation of the assay. CD4+ T cells are cultured at a 
limiting dilution under conditions whereby a single virus emerges from the latent reservoir 
in each positive well (red). The number of infectious units per million (IUPM) is determined 
directly from the number of p24-positive wells. Virus-containing supernatants from 
















Unlike QVOA, where multiple dilutions are assayed to determine the frequency of infected 
cells, Q2VOA is performed using a single predetermined dilution that produces less than 
30% positive wells. This maximizes the total number of individual viruses that can be 
quantified and then subsequently phenotypically assayed by sequencing or antibody 
neutralization. Based on Poisson distribution, this technique produces individual viral 
outgrowth cultures that are likely to contain single replication-competent proviruses 
(Figure 3.1). 
CD4+ T lymphocytes were isolated from each of four chronically infected 
individuals who had been virologically suppressed by combination ART for 4–22 years, 
at two time-points 4–6 months apart (Table 3.1). Between 0.40–1.44 × 108 CD4+ T 
lymphocytes from each ART-treated individual were tested at each time point. On 
average, 13.5% of cultures were positive for p24. The number of cells yielding replication-
competent viruses varied across individuals from 0.19 to 1.07 infectious units per million, 
which is similar to values obtained by others (Laird et al., 2013) (Table 3.2). 
Table 3.1 Clinical Characteristics of Study Subjects. 










on ART ART regimen 
B106 27 M 2008 390 7 7 TDF/FTC/RPV 
B115 44 M 1993 200 22 22 DRV/r, ABC, 3TC 
B155 59 M 1993 444 22 15 TDF/FTC/RPV 
B199 49 M 2009 200 6 4 TDF/FTC, RAL 
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Table 3.2 Overall Q2VOA results and IUPM 
To characterize the cultured viruses molecularly, cDNA was produced from culture 
supernatants and sequenced the env gene using primers that resulted in a clonal 
prediction score of 94 of 100 (silicianolab.johnshopkins.edu/cps) (Laskey et al., 2016). 
Thus, there was a high probability that identical env sequences represented identical full-
length genomes. 234 env sequences were obtained from Q2VOA, of which 13.7% were 
excluded from further analysis due to the presence of short reads (3.8%) or the presence 
of reads producing an inconclusive consensus (9.8%). The phylogenetic analysis of the 
remaining 202 env sequences showed that the four individuals were infected with 
epidemiologically unrelated clade B viruses (Figure 3.2). Phylogenetic analysis of 
individual sequences revealed the existence of a diverse viral population composed of 
multiple (bootstrap-supported) clusters for each of the four individuals (Figure 3.3a). 
To compare the diversity of viruses obtained from a “bulk” culture with the diversity 
of viruses derived by Q2VOA, single genome analysis (SGA) was performed on bulk 
culture supernatants established at the same time from the same four individuals. 














wells (%) IUPM 
Study ID Time point 1 Time point 2 
B106 4 39.6 x 106 132 31 (23.5) 0.89 75.6 x 106 252 28 (11.1) 0.39 
B115 4 57.6 x 106 192 40 (20.8) 0.57 140 x 106 468 50 (10.7) 0.38 
B155 6 75.6 x 106 252 69 (27.4) 1.07 72 x 106 240 24 (16.7) 0.35 
B199 4 43.2 x 106 144 24 (16.7) 0.61 144 x 106 480 26 (5.4) 0.19 
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Figure 3.2 Four individuals are infected with epidemiologically unrelated clade B 
viruses. Maximum likelihood phylogenetic tree was constructed from viral env sequences 
from outgrowth culture supernatants as well as archived proviral DNA from all 
participants. Hypervariable (as defined in  
https://www.hiv.lanl.gov/content/sequence/VAR_REG_CHAR) and other poorly aligned 
regions were excluded from the analysis. The tree was constructed using RAxML v. 
8.0.22 (55) with a GTRGAMMA substitution model, with 1,000 bootstrap replicates and 













Figure 3.3 Env sequences from outgrowth cultures. a) Maximum likelihood 
phylogenetic trees of full-length env sequences of viruses from Q2VOA outgrowth 
cultures from four individuals. Viruses from time point 1 are green, viruses from time point 
2 are red, and bulk culture SGA is gray. Asterisks indicate nodes with significant bootstrap 
values (bootstrap support ≥ 70%). Numbers next to sequences correspond to viruses 
assayed for neutralization in Fig. 6. b) Pie charts depict the distribution of culture-derived 
env sequences from the two time points. The number in the inner circle indicates the total 
number of env sequences analyzed. White represents sequences isolated only once 
across both time points, and colored areas represent identical sequences that appear 
more than once. The size of the pie slice is proportional to the number of sequences in 
the clone. Clones found at both time points are the same color and denoted by asterisks. 
Percentages of identical sequences are displayed at the bottom right of each pie chart. 
c) Representation of overlapping sequences between the two time points. The size of the
hemisphere is proportional to the number of sequences. Light blue hemispheres 
represent overlapping sequences and gray hemispheres represent the total number of 




























































































































T1 T2 T1 T2 T1 T2
46 
Table 3.3 Distribution of observed sequences in Q2VOA. 
In contrast to Q2VOA, bulk culture supernatants were mainly monotypic and showed 
much reduced overall diversity (Figure 3.3a). Thus, when multiple infected cells are 
reactivated in a single culture, the strain or strains with the fastest growth kinetics, or the 
greatest fitness in culture, dominate. 
Stability of replication competent reservoir over time 
Individual replication-competent viruses obtained from different Q2VOA cultures 
frequently encoded identical env sequences. When Q2VOA-derived viruses obtained at 
the two time points were compared for each subject, typically less than half (40–52%) of 
their env sequences were unique (Table 3.3). 
The majority of sequences were identical to at least one other independently derived 
replication-competent virus obtained from the same subject. For example, of a total of 49 
env sequences isolated from the two time points from B106, only 21 were unique. The 
majority (22) were identical to at least one other sequence that appeared at one of the 
two time-points. Irrespective of whether they appear at one or both time points, these 
repeated sequences will be referred to as “clones” because they must originate from at 
Table 2.3. Distribution of observed sequences in Q2VOA
Non-clonal Clonal Overlapping 
Study ID T1 T2 Total (%) T1 T2 Total (%) 
sequences between 
T1 and T2 (%) 
B106 13 8 21/49 (42.9) 12 16 28/49 (57.1) 23/49 (46.9) 
B115 9 15 24/50 (48.0) 10 16 26/50 (52.0) 23/50 (46.0) 
B155 13 8 21/53 (39.6) 19 13 32/53 (60.4) 21/53 (39.6) 
B199 10 16 26/50 (52.0) 13 11 24/50 (48.0) 20/50 (40.0) 
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least two different CD4+ T cells. This finding does not necessarily imply that the viruses 
are integrated in the same location in the genome because it is possible that identical 
viruses can infect different CD4+ T cells. The size of these clones ranged from two to 10 
members, with a mean of 3.69 when all four individuals and both time points were 
considered (Figure 3.3b, c and Table 3.3). Fifty-four percent of all replication-competent 
viruses emerging in Q2VOA cultures were derived from expanded clones (Figure 3.3b, c 
and Table 3.3). 
To determine whether the viral sequences obtained from the replication-competent 
reservoir remained stable over time, the sequences from the two time points for each 
individual were compared. Many branches in the phylogenetic trees contained sequences 
derived from both time points (Figures 3.3a-c and Table 3.3). The relationship between 
the sequences from both time points was formally assessed by determining their 
Genealogical Sorting Index (GSI), which quantitates the degree of phylogenetic 
association between sequences (Cummings et al., 2008). GSI values, which range 
between 0 (complete interspersion) and 1 (complete monophyly), showed that for each 
of the four individuals, the sequences obtained by Q2VOA from both time points could not 
be segregated as distinct groups (Table 3.4). This finding demonstrates that the viral 
population emerging from the latent reservoir in four individuals was stable over the 4- to 
6- month time interval analyzed. 
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Table 3.4 GSI and probability values for HIV env trees under the null hypothesis 
that Q2VOA-derived sequences from both visits are a single mixed group. 
Comparison of replication competent viruses with proviral sequences 
To examine the relationship between proviruses integrated into CD4+ T-cell DNA 
and the replication-competent viruses obtained by Q2VOA, SGA on DNA isolated from 
primary CD4+ T lymphocytes was performed from the same individuals at both time 
points. We obtained a total of 498 env sequences, of which 16.3% were excluded from 
further analysis due to the presence of hypermutated regions (2.4%), short reads (5.6%), 
or reads producing an inconclusive consensus (8.2%). The remaining 417 full-length env 
sequences, or 85–113 per individual, fell within the same four patient-specific clades as 
the Q2VOA-derived env sequences, indicating absence of sample mix-up or 
contamination (Figure 3.2). 
As previously reported for archived proviral DNA amplified from primary CD4+ T 
cells, we found unique sequences, as well as large groups of identical sequences, 
marking presumptive expanded cell clones (Cohn et al., 2015; Maldarelli et al., 2014; von 
Stockenstrom et al., 2015; Wagner et al., 2013; Wagner et al., 2014). For example, in 
B106, 67 of 113 env sequences obtained from the two time points were unique and the 
remaining 46 were members of clones. In addition, 36 of the 46 identical sequences 
overlapped between the two time points (Figures 3.4a and b and Table 3.5). Thus, like 
Q2VOA 
Visit 1 Visit 2 
 Study ID GSI P-value GSI P-value 
B106 0.067 0.45 0.02 0.92 
B115 0.066 0.14 0 1 
B155 0.059 0.26 0.012 0.82 
B199 0.053 0.3 0 1 
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the Q2VOA-derived sequences, the archived proviral population was stable over the time 
interval analyzed. 
Table 3.5 Distribution of observed sequences in proviral DNA 
Archived proviral DNA sequences were then compared with replication-competent 
Q2VOA-derived sequences. Because both the proviral DNA and the replication-
competent viral sequences for any given individual were overlapping at the two time 
points, we combined each of the two sets of sequences (Figure 3.5). As might be 
expected, given that the sample size is limited, we found relatively limited overlap 
Non-clonal Clonal Overlapping 
Study ID T1 T2 Total (%) T1 T2 Total (%) 
sequences between 
T1 and T2 (%) 
B106 30 37 67/113 (59.3) 13 33 46/113 (40.7) 36/113 (31.9) 
B115 6 43  49/85 (57.6) 6 30 36/85 (42.4) 10/85 (11.8) 
B155 6 23  29/99 (29.3) 28 42 70/99 (70.7) 58/99 (58.6) 
B199 39 9 48/120 (40.0) 50 22 72/120 (60.0) 70/120 (58.3) 
50 
Figure 3.4 Env sequences from archived proviral DNA. a) Maximum likelihood 
phylogenetic trees of full-length env sequences derived by SGA from primary CD4+ T 
cells from four individuals. Viruses from time point 1 are green, and viruses from time 
point 2 are red. Asterisks indicate nodes with significant bootstrap values (bootstrap 
support ≥ 70%). b) Pie charts depict the distribution of archived env sequences from the 
two time points. The number in the inner circle indicates the total number of env 
sequences analyzed. White represents unique sequences isolated only once across both 
time points, and colored areas represent identical sequences that appear more than once. 
The size of the pie slice is proportional to the number of sequences in the clone. Clones 
found at both time points are the same color and denoted by asterisks. Percentages of 
identical sequences are displayed at the bottom right of each pie chart. c) Representation 
of overlapping sequences between the two time points. The size of the hemisphere is 
proportional to the number of sequences. Light blue hemispheres represent overlapping 
sequences and gray hemispheres represent the total number of sequences. The  
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between the archived proviral sequences and Q2VOA culture-derived sequences in 
phylogenetic trees, with multiple large clusters composed of sequences isolated from only 
a single source (Figure 3.5a). The 417 archived proviral sequences contained 50 
expanded clones, 12 of which were also found in the replication-competent outgrowth 
cultures. The relative frequency of expanded clones from these two sources differed: 
Some greatly expanded clones identified in primary CD4+ T-cell DNA represented only a 
small fraction of clones identified in the outgrowth cultures, and rare archived clones were 
disproportionally abundant among the reactivated latent replication-competent viruses 
(Figure 3.5b). This finding is best illustrated in subject B155, where the largest archived 
proviral clone, which comprised 28 of 99 total sequences, was found only once among 
52 replication-competent viruses (Figures 3.5b and c). In contrast, in B199, one archived 
proviral sequence, which appeared only once in a total of 120 sequences derived from 
primary CD4+ T-cell DNA, was found in 11 of 50 Q2VOA culture-derived sequences 
emerging from the latent reservoir. B115 provided the clearest example of the 
discrepancy between proviral DNA and cultured viruses, with no instances of matching 
sequences between 85 proviral sequences and 50 outgrowth viruses (Figures 3.5b and 
c). Although this discrepancy is most likely due to the prevalence of defective archived 
proviral sequences (Bruner et al., 2016; Cohn et al., 2015; Eriksson et al., 2013; Ho et 
al., 2013), differences in proviral accessibility to polymerase may also contribute. 
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Figure 3.5 Comparison of env sequences from archived proviruses and replication-
competent viruses. Sequences from the two time points were pooled for each 
participant. a) Maximum likelihood phylogenetic trees of env sequences. Limiting dilution 
outgrowth viruses are red, bulk culture viruses are gray, and viral sequences amplified 
from primary CD4+ T cells are blue. Asterisks indicate nodes with significant bootstrap 
values (bootstrap support ≥ 70%). b) Pie charts depicting the distribution of archived 
proviruses and culture-derived sequences. The numbers in the inner circles indicate the 
total number of env sequences analyzed. White represents sequences isolated only once, 
and colored areas represent identical sequences. The size of the pie slice is proportional 
to the number of sequences in the clone. Clones found in proviral DNA and outgrowth 
cultures are the same color and denoted by asterisks. Percentages of identical groups of 
sequences are displayed at the bottom right of each pie chart. c) Representation of 
overlapping sequences between the two sources. The size of the hemisphere is 
proportional to the number of sequences. Light blue hemispheres represent overlapping 
sequences and gray hemispheres represent the total number of sequences. The 
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between the archived proviral sequences and Q2VOA culture-derived sequences in 
phylogenetic trees, with multiple large clusters composed of sequences isolated from only 
a single source (Figure 3.5a). The 417 archived proviral sequences contained 50 
expanded clones, 12 of which were also found in the replication-competent outgrowth 
cultures. The relative frequency of expanded clones from these two sources differed: 
Some greatly expanded clones identified in primary CD4+ T-cell DNA represented only a 
small fraction of clones identified in the outgrowth cultures, and rare archived clones were 
disproportionally abundant among the reactivated latent replication-competent viruses 
(Figure 3.5b). This finding is best illustrated in subject B155, where the largest archived 
proviral clone, which comprised 28 of 99 total sequences, was found only once among 
52 replication-competent viruses (Figures 3.5b and c). In contrast, in B199, one archived 
proviral sequence, which appeared only once in a total of 120 sequences derived from 
primary CD4+ T-cell DNA, was found in 11 of 50 Q2VOA culture-derived sequences 
emerging from the latent reservoir. B115 provided the clearest example of the 
discrepancy between proviral DNA and cultured viruses, with no instances of matching 
sequences between 85 proviral sequences and 50 outgrowth viruses (Figures 3.5b and 
c). Although this discrepancy is most likely due to the prevalence of defective archived 
proviral sequences (Bruner et al., 2016; Cohn et al., 2015; Eriksson et al., 2013; Ho et 
al., 2013), differences in proviral accessibility to polymerase may also contribute. 
To determine the extent to which sequences from replication- competent viruses 
and archived proviruses were compartmentalized, we calculated their GSI. This analysis 
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demonstrated that archived proviral and Q2VOA culture-derived sequences were 
significantly segregated for every single individual analyzed (Table 3.6). Thus, proviral 
sequences derived from primary CD4+ T-cell DNA do not provide an accurate 
representation of viruses comprising the replication-competent reservoir. 
Table 3.6 GSI and  probability values for HIV env trees under the null hypothesis
 
that Q2VOA-derived sequences and proviral-derived sequences are a single 
mixed group.  
To understand the relationship between the two groups of sequences better, we 
analyzed them by a mathematical model that describes every sequence by two variables. 
The first (p) is the frequency of a sequence in the proviral compartment, and the second 
(r) is its probability of reactivation in the active viral culture. These parameters were 
extracted from the experimental data using Bayesian inference methods. The data show 
that clone size is negatively correlated with the activation probability (r = −0.94, p = 3.4 × 
10−34) (Figure 3.6). These results indicate that the larger the clone of archived proviral 
sequences, the lower is its probability of representing a replication-competent virus in the 
Q2VOA culture. 
Q2VOA Proviral 
Study ID GSI P-value GSI P-value 
B106 0.184 <0.01 0.114 <0.001 
B115 0.61 <0.001 0.43 <0.001 
B155 0.421 <0.001 0.125 <0.001 




Figure 3.6 Negative correlation between proviral clone size and probability of 
reactivation in culture. The frequency of integrated provirus (p) is negatively correlated 
with its probability of reactivation in culture (r). Bars denote interquartile ranges of 
posterior parameter estimates. The Pearson correlation is computed using median values 
for large clones. Clones with diverse frequencies and reactivation probabilities are 


























LATENT CELL CAPTURE AND CHARACTERIZATION 
Latency capture enriches HIV-1 RNA producing cells 
To investigate the cells that contribute to the latent reservoir, I developed a method 
to enrich and isolate reactivated latent cells by combining antibody staining, magnetic 
enrichment, and flow cytometry (Pape et al., 2011) (latent cell capture, or LURE). Purified 
CD4+ T cells from ART suppressed donors were activated with PHA, a robust in vitro 
latency reactivation agent, for 36h in the presence of 5 potent antiretroviral drugs to 
prevent new infection and virion maturation, and a pan-caspase inhibitor to reduce cell 
death associated with active infection. Reactivated latent cells expressing surface HIV-1 
Envelope (Env) protein were labeled with a cocktail of biotinylated anti-Env broadly 
neutralizing antibodies (bNAbs), streptavidin-PE, and anti-PE magnetic beads, followed 
by enrichment over a magnetic column (Figure 4.1). 
Figure 4.1 Diagrammatic representation of latency capture (LURE) protocol. CD4+ 
T cells from ART suppressed donors are cultured in conditioned media with PHA, IL-2, 
antiretroviral drug cocktail and pan-caspase inhibitor for 36h. Cells are labeled with a 
biotinylated bNAb cocktail, followed by Streptavidin PE and anti-PE magnetic beads, 















Our anti-Env antibody cocktail consists of 3BNC117 (Scheid et al., 2011), 10-1074 
(Mouquet et al., 2012), and PG16 (Walker et al., 2009), that together cover over 90% of 
all viral envelopes (Yoon et al., 2015). 
Relative enrichment of the magnetically isolated, Env+ cellular fraction was 
measured by comparison to unfractionated control cells from the same culture by flow 
cytometry (Figure 4.2) and by quantitative PCR for HIV-1 gag mRNA (Figure 4.3a). 
Figure 4.2 Enrichment Env expressing cells by LURE. Dot plots show Env vs. CD4 
staining on pre-enrichment control and positively selected cells for all donors. Gate shows 




















Figure 4.3 HIV-1 RNA enrichment in cells isolated by LURE. a) HIV-gag mRNA was 
measured in equivalent numbers of Env+ and control cells. Graph shows results of qPCR 
(12.8-copy limit of detection) for HIV-gag mRNA, normalized to the number of sorted cells. 
p = 0.002, Wilcoxon matched-pairs signed rank test. b) HIV-gag mRNA was measured in 
equivalent numbers of Env+ and unstimulated CD4+ T cells. Graph shows results of 
qPCR (12.8-copy limit of detection) for HIV-gag mRNA, normalized to the number of 






























































































Enrichment of cell associated HIV-1 RNA was entirely dependent on cellular activation 
with PHA (Figure 4.3b). The degree of enrichment achieved by magnetic columns was 
measured in samples from 10 individuals and was found to be dependent in part (r2 = 
0.5609, p = 0.0127) on the size of the latent reservoir as measured by viral outgrowth 
assays in infectious units per million (IUPM) (Figure 4.3c). 
For example, participant B207 has an IUPM of 16 and a relative enrichment of HIV-
1 gag RNA of 3000-fold, participant 610 an IUPM of 1.95 and a 66-fold enrichment, and 
participant 601 has an IUPM of 0.49 and only a 3-fold enrichment (Figure 4.3c).  We 
conclude that reactivated latently infected cells can be enriched based on HIV-1 Env 
surface expression. 
Full length virus recovered by single-cell RNA Sequencing 
To further purify the reactivated latent cells, we used flow cytometry to sort single 
cells from the magnetically enriched fraction based on Env staining. Individual cells 
expressing both env and gag were identified by the combination of surface Env staining 
and single cell HIV-1 gag mRNA expression. The frequency of gag mRNA expressing 
single cells in individuals with high IUPMs ranged from 10-50% of sorted cells (603 and 
B207, IUPM 3.17 and 16 respectively, Table 4.1). In individuals with relatively lower 
IUPMs (0.49-2.43), the percent of Env+gag+ single cells isolated varied from 0-4% (12 
individuals were examined: Env+gag+ single cells were isolated from 10 of the 12, Table 
4.1). 
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To obtain a more comprehensive understanding of the nature of the cells captured by 
LURE and the viruses they harbor, we performed single cell RNA sequencing 
(scRNASeq). Donors 603, 605 and B207, were selected based on length of ART therapy 
(undetectable viremia for 11-15 years), sample availability, and the range of IUPMs (603: 
3.17, 605: 0.71 and B207: 16). We profiled the transcriptome of 2 groups of cells obtained 
from these 3 individuals: reactivated gag+Env+ single cells captured by LURE, and 
control unfractionated single cells from the exact same PHA activated culture. In addition, 
Table 4.1 Patient demographics and LURE experiments. ART abbreviations, ATV: 
atazanavir, R: ritonavir, ABC: abacavir, 3TC: lamivudine, RPV: rilpivirine, FTC: 
emtricitabine, TDF: tenofovir disoproxil, RAL: raltegravir, EFV: efavirenz, LPV: lopinavir, 
EGV: elvitegravir, TAF: tenofovir alafenamide, cobi: cobicistat. Env+ bulk gag RNA 
enrichment, LURE: gag RNA enrichment performed on immunomagnetically isolated 
Env+ cellular fraction. YES: significant enrichment in Env+ fraction compared to controls. 
ND: not done. Single Cell LURE: single cell sort of Env+ enriched LURE cells. YES: gag+ 
cells identified by single cell qPCR. NO: no gag+ cells identified by single cell qPCR.  
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we performed scRNASeq on activated CD4+ T cells that were productively infected with 
HIV-1YU2 (YU2) in vitro and purified by cell sorting using anti-Env antibodies (Figure 4.4). 
Figure 4.4 Gating strategy for HIV-1YU2 infected cells. Cells infected in vitro with 
HIV-1YU2 for 2 days were FACSorted by gating on Env+CD4lo cells.  
Overall 249 cells were characterized, of which 22 cells (8.8%) were removed by quality 
metrics (Gaublomme et al., 2015). Of the 227 cells retained, 33 were YU2 infected cells, 
85 were cells captured by LURE, and 109 were unfractionated control cells from the same 










Figure 4.5 Number of genes detected per cell. Results of single cell RNASeq showing 
saturation of genes detected.  
 
As expected based on the rarity of infected cells in the unfractionated, activated control 
cells (£1.6X10-5), HIV reads were not detectable in these samples (Figure 4.6). In 
contrast, cells captured by LURE and YU2 infected cells showed similar percentages of 
total mRNA reads mapping to the HIV-1 genome (3.8 and 4.5% respectively, as expected 
(Sherrill-Mix et al., 2015)) (Figure 4.6). We conclude that scRNASeq performed on 
reactivated latent cells captured by LURE contains RNA sequences mapping to the 
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Figure 4.6 Frequency of HIV-1 reads detected in single cell RNA Seq libraries. 
Fraction of reads mapping to HIV-1 in unfractionated control, LURE purified gag+Env+, 
and YU2 infected scRNASeq libraries.  
To determine whether the reactivated cells captured by LURE express intact viruses, we 
used Iterative Virus Assembler software to reconstruct the virus from scRNASeq reads in 
each individual CD4+ T cell (Hunt et al., 2015). HIV RNA recovered by scRNASeq was 








































Figure 4.7 HIV-1 splice sites identified in single cell RNASeq libraries. Junctions 
between HIV splice donors and acceptors observed in RNASeq data. Acceptors are 
shown as the columns and donors as the rows with the coloring indicating the frequency 
of reads identified containing indicated splice junction.  
 
We were able to fully reconstruct virus from 26 of 32 individual cells infected with YU2 
(Figure 4.8a).  
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Figure 4.8 Full length virus sequences recovered by scRNASeq. Map of individual 
viruses reconstructed from scRNASeq. Each horizontal bar represents a single virus from 
an individual cell. Solid bars and arrows indicate that the entire virus was reconstructed 
from scRNASeq reads. Outlined, lighter colored bars indicate incomplete genome 
reconstruction. Different colors indicate different sequences. For participants 603 and 
605, every virus identified was identical. For B207, we identified 4 unique viruses, with 
one clone (in red) predominating. 
Among the reactivated cells captured by LURE, we were able to fully reconstruct viruses 
from 12 cells from 603, 2 from 605 and 5 from B207, while the viruses in the remaining 
LURE cells were partially reconstructed (Figure 4.8b). Every virus sequence obtained by 
scRNASeq in 603 and 605 belonged to a single expanded viral clone (Figure 4.8b). In 


































































B207, we identified 4 different viruses: the first virus was found in 30 cells. From these 30 
cells expressing identical virus, we were able to reconstruct the full virus from 4 cells while 
in the remaining 26 cells the virus was partially reconstructed; the second virus was found 
in a single cell and was fully reconstructed; the third virus was found in a single cell and 
was only partially reconstructed; the fourth virus was found in 2 cells and was also only 
partially reconstructed (Figure 4.8b). Finally, all of the fully reconstructed viruses obtained 
from scRNASeq libraries were completely intact when analyzed by Gene Cutter software. 
Thus, the combination of LURE and scRNASeq can be used to recover full length, intact 
HIV-1 from single reactivated latent cells. 
 
Captured cells express functional virus 
 Replication competent latent viruses obtained in viral outgrowth cultures show Env 
sequences that segregate from the majority of defective proviruses found by single 
genome analysis (SGA) (Bui et al., 2017; Lorenzi et al., 2016). To determine whether the 
full-length viruses expressed in the purified single cells obtained by LURE correspond to 
the intact latent viruses that emerge in viral outgrowth assays, we compared their Env 
sequences (Figure 4.9).  To do so, we performed quantitative and qualitative viral 
outgrowth assays (Q2VOA) (Lorenzi et al., 2016), Env SGA on DNA isolated from CD4+ 
T cells, and compared these sequences to those found in LURE cells.  
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Figure 4.9 Captured cells express Env that is identical to latent virus emerging in 
Q2VOA. Maximum likelihood phylogenetic trees compare full length Env sequences 
derived from single cells capture by LURE (solid and open circles), DNA proviruses (open 
squares) and replication-competent single cell viral outgrowth cultures (Q2VOA) (open 
triangles) from participants 603, 605, and B207. Sequences from LURE cells were 
obtained either by recovery and assembly from RNASeq reads (closed circles) or from 
reverse transcription of RNA in single cells followed by specific Env PCR from single 
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Phylogenetic analysis of Env sequences revealed that in donors 603 and B207 the Env 
sequences obtained by LURE and Q2VOA generally clustered together, were part of an 
expanded clone, and did not overlap significantly with sequences obtained by proviral 
DNA SGA (Figure 4.9). Participant 605 has an unusual distribution of DNA SGA proviral 
sequences in that there is a significant overlap with the Env sequences found in viral 
outgrowth cultures. Nevertheless, the majority of LURE derived Env sequences belong 
to the major viral outgrowth clone found in Q2VOA (Figure 4.9) in all three individuals. We 
conclude that the Env sequences expressed by cells purified by LURE are typically 
identical to those found in viruses that emerge from latent cells in viral outgrowth cultures 
and therefore are replication competent. 
Clones of infected cells in replication competent reservoir 
The idea that latent cells harboring identical replication competent viruses arise by 
clonal expansion is supported by observations that latent cells can divide in vitro, identical 
replication competent viruses can arise from multiple cells, and by proviral integration site 
mapping (Bui et al., 2017; Cohn et al., 2015; Hosmane et al., 2017; Lee et al., 2017; 
Lorenzi et al., 2016; Maldarelli et al., 2014; Mullins and Frenkel, 2017; Simonetti et al., 
2016; Wagner et al., 2014). However, a less likely alternative interpretation is that latency 
is established during a viral replicative burst and that identical viruses are integrated into 
the genome of a diverse group of T cells. To distinguish between clonal expansion and a 
possible replicative burst, we analyzed the T cell receptor (TCR) sequences obtained 
from single latent cells captured by LURE. CD4+ T cells express unique antigen receptors 
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produced by random TCR variable, diversity and joining gene segment (VDJ) 
recombination. T cells with identical TCRs are only produced by clonal expansion.  
 
Figure 4.10 Captured cells represents clones of expanded CD4+ T cells. a) TCR 
sequences amplified by PCR in single sorted CD4+ T cells. The number in the center of 
the pie denotes the number of cells sequenced; yellow slice is a unique clone consisting 
of two members. The single clone in B199 was identified by shared TCR alpha and beta 
sequence. b) TCR sequences recovered from scRNASeq or amplified by PCR, for control 
(unfractionated pre-enrichment) and gag+Env+ LURE purified cells. The number in the 
center of the pie denotes the number of cells sequenced; slices are proportional to clone 
size showing unique TCRs (white slices) and clonal TCRs (colored slices). Clones were 
identified by their shared TCR alpha and beta sequences. 
 
As a control, we obtained TCR sequences from nearly 600 single CD4+ T cells from 3 




























sequences were unique, with only a single 2-member clone identified in 1 of the 6 
individuals (Figure 4.10a). In contrast, the TCR sequences derived from the latent cells 
with identical proviruses captured by LURE (Figure 4.9) were entirely clonal in all 3 donors 
(Figure 4.10b). To rule out the possibility that the observed clonality was due in part to T 
cell division in vitro, we labeled cells with CFSE and found that there was no measurable 
T cell division in 36h under our culture conditions (data not shown). We conclude that 
groups of latent cells containing identical replication competent viruses are products of 
CD4+ T cell clonal expansion in vivo.  
 
Distinct gene signature identified in reactivated latent cells 
 To further characterize the reactivated latent cells captured by LURE, we 
performed single-cell transcriptome analysis, and compared the results to unfractionated, 
PHA stimulated control cells from the same cultures, and to activated CD4+ T cells 
productively infected with YU2. We included these controls to ensure that any 
differentially expressed genes or gene signatures would be specific to reactivated latent 
cells, and not to differences between infected individuals, PHA activation, or active 
infection. We performed hierarchical clustering using a principal-component analysis 
(PCA) called Seurat (Satija et al., 2015) using gene expression data from the 227 cells. 
Seurat identifies significant cell clusters by performing density-based clustering on a two-
dimensional t-distributed Stochastic Neighbor Embedding (t-SNE) map of the total gene 
expression data. This unbiased analysis identified three unique groups of genes that 
segregated the cells into three separate clusters. Each of these clusters was found to 
correspond to one of the three input groups: control, LURE, and YU2 infected cells (Figure 
 
 74 
4.11).  Additional analysis which employs unsupervised clustering using all gene 
expression data (Single-cell Consensus Clustering, or SC3), confirmed these results 
comparing control to LURE cells (Figure 4.12). Thus, reactivated latent cells captured by 
LURE cluster separately from uninfected (control) and actively infected CD4+ T cells by 
PCA and unsupervised clustering.  
 
Figure 4.11 Principal components analysis (PCA) clusters cells by group. Shown 
is the Seurat t-SNE displayed output for the three groups. Plot shows single cells 
(Control (black), Env+ LURE (orange) and YU2 (gray)). Seurat analysis identified 3 
distinct clusters of genes which define three groups of cells (circles (gene cluster 0), 
triangles (gene cluster 1) and squares (gene cluster 2)) by performing graph-based 




















































































































Figure 4.12 Single-cell clustering segregates control from LURE Env+gag+ cells. 
a) Single-cell consensus clustering (SC3) was used to cluster cells in an unsupervised 
manor. Color spectrum assigns cells to different clusters, with blue indicating 
assignment to a different cluster and red indicating cells in the same cluster. b) SC3-
identified marker genes which are highly expressed in only one of the clusters and are 
able to distinguish it from all the remaining ones (blue: low expression, red: high 





























































To further understand the transcriptional differences between the three groups of cells, 
we identified differentially expressed genes (DEG) (p < 0.01) between reactivated latent 
cells and PHA activated control cells. Using unsupervised clustering, we grouped the 
cells based on the expression of all significantly differentially expressed genes between 
LURE and control cell groups (p<0.01, 778 genes). We find that irrespective of donor, 
reactivated cells purified by LURE generally segregate from unfractionated, activated 
control cells in 2 of 3 individuals (Figure 4.13a), with cells from the third individual split 
between the LURE group and control group. Similar results were also obtained by 
comparison with YU2 infected cells (Figure 4.13b). We conclude that cells captured by 
LURE segregate from activated control cells and productively infected cells by three 




Figure 4.13 Differential gene expression clusters LURE cells from controls. Heat-
maps show unsupervised clustering of differentially expressed genes between the 
gag+Env+ LURE purified group (orange bars) and control unfractionated group (black 
bars) and YU2 infected cells (gray bars). Cells from donor 603 are indicated in blue, 605 
in green, and B207 in red. Color indicates the normalized level of expression. 
 
Among the 240 genes which overlapped between the PCA and DEG (p < 0.01) (gene list 



































have been shown by independent analyses to be associated with HIV-1 latency including 
microRNAs, chemokines, long non-coding RNAs and transcription factors (Figure 4.14a). 
For example, cell surface markers associated with latency Tigit (Baxter et al., 2016; 
Fromentin et al., 2016) and HLA-DR (Cockerham et al., 2014) were 140 and 76-fold up-
regulated in cells purified by LURE (Figure 4.14a). CD32a (Descours et al., 2017) was 
not found by RNASeq or FACS analysis (Figure 4.14b). MiR-155, which inhibits TRIM32, 
prevents its interaction with HIV tat and reinforces viral latency (Ruelas et al., 2015), was 
368 times more highly expressed in Env+Gag+ cells purified by LURE compared to 
controls. Chemokine CCL3, which is reported to have HIV-1 suppressive effects 
(Abdelwahab et al., 2003; Hudspeth et al., 2012), is expressed 795 times higher in 
Env+Gag+ cells purified by LURE compared to controls. Finally, a number of transcription 
factors were among the top 15 differentially expressed genes, including the top 
differentially expressed gene, PRDM1 (1365x). PRDM1 represses HIV-1 proviral 
transcription in memory CD4+ T cells by inhibition of HIV tat (Kaczmarek Michaels et al., 
2015), and its overexpression is associated with lower levels of HIV-1 transcription in elite 





Figure 4.14 Selected gene expression in LURE cells compared to controls. a) 
Graphs show expression of selected genes in individual gag+Env+ LURE purified and 
control unfractionated cells as determined by MAST software in participants 603 (blue), 
605 (green), B207 (red). b) Single cell index sorting was performed on Env+ enriched 
cells from participant B207 followed by RNA isolation, cDNA synthesis and gag qPCR. 
Gag+ cells were then examined for CD32a, Env and CD4 expression by index sorting. 
Shown is the mean fluorescence in gag+ and gag- cells from the same experiment.  
 
To further examine the differences between LURE and control cells, we performed 
enrichment analysis using the Gene Ontology database with the 240 genes that 
overlapped between the DEG and PCA analyses. Among the top ten most significantly 
enriched biological processes, eight are related to immune system function, suggesting 
that PHA stimulated LURE and control cells differ in their expression of genes related to 
responses to pathogens. For example, LURE and control cells differ markedly in response 
to type I interferon and regulation of type I interferon production with control cells having 
higher expression of type I interferon responsive genes such as IFIT3, ISG20, IRF1, IFI6, 
RSAD2, STAT1, XAF1, CTNNB1 and UBE2L6. Consequently, the control cells also show 
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ISG20, IRF1, SERINC5, IL2RA, RSAD2, DDIT4, STAT1, and PIM2. Thus, reactivated 
latent cells display a gene expression program that is consistent with their being less 
responsive to stimuli associated with viral infection than control cells obtained from the 
same cultures. Consistent with the altered gene expression program in reactivated latent 
cells, LURE and control cells show significant differences in the expression of genes that 
regulate transcription. For example, reactivated latent cells have higher levels of 
expression of transcriptional regulators PRDM1, MAF, IRF4, MTDH, IKZF3, and BATF3, 
whereas control cells have higher expression of PIM2, STAT1, HNRNPA2B, EZR, IRF1, 
CTNNB1 and NFKBIZ. We conclude that reactivated latent cells differ from control cells 








 The search for an HIV-1 cure has been ongoing for nearly 4 decades. Discovery 
and widespread use of antiretroviral therapy (ART) has dramatically slowed progression 
of AIDS in infected individuals (Arts and Hazuda, 2012), and is efficacious in preventing 
HIV transmission (Grant et al., 2010). However, existing therapies are not curative, due 
to the presence of latently infected cells which persist for the lifetime of infected individuals 
and are responsible for viral rebound if therapy is interrupted – requiring lifelong 
adherence to ART. Further consequences of nonadherence to antiretroviral drugs are the 
development of drug resistance mutations (Nachega et al., 2011) and possibly an 
increased latent reservoir size (Jain et al., 2013; Sarmati et al., 2015). Since the first 
description of the latent reservoir in 1997 (Chun et al., 1997a; Chun et al., 1997b), 
thousands of papers have been published attempting to describe, characterize, quantify 
and understand latently infected cells.  
 Latently infected cells are primarily CD4+ T cells, though other immune cell 
subsets and even non-immune cells in the brain have been described harboring HIV-1 
DNA (Barton et al., 2016). In persons on suppressive ART, inducible latent cells in the 
blood number one per million CD4+ T cells. These cells are believed to harbor a quiescent 
provirus such that no viral RNAs, and therefore no viral proteins, are produced. Thus, the 
absence of any identifying surface marker, combined with their dramatic rarity has 
rendered isolation of these cells for study extremely difficult. Additionally, the 
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overabundance of proviruses with internal defects has confounded quantification of the 
replication competent reservoir.  
 In this thesis, I describe our efforts to characterize the latent reservoir in HIV-1 
infected ART suppressed adults. We took three single cell approaches to describe latently 
infected cells. First, we used integration site sequencing to map large numbers of HIV-1 
integration sites from single cells (Cohn et al., 2015). Upon the discovery that the majority 
of large expanded infected cell clones harbor defective virus, we performed a single-cell 
assay to characterize only replication competent viruses using the Quantitative and 
Qualitative Viral Outgrowth Assay (Q2VOA) (Lorenzi et al., 2016). This method allowed 
the sequencing and phenotypic characterization of replication competent viruses arising 
from single cells. The discovery of identical replication competent sequences in multiple 
cells suggested that cells harboring replication competent virus may infrequently divide in 
vivo. The Q2VOA characterizes of reservoir viruses, not the cells from which the virus 
originates as they are dead by the time virus is detectable by current methods. To 
characterize the latent cells themselves, we developed and isolation strategy which we 
call Latency Capture (LURE) (Cohn et al., In Press at the time of thesis printing). This 
strategy allowed us characterize the latent reservoir by simultaneously performing gene 
expression studies, TCR sequencing, and whole virus reconstruction from single recently 
reactivated latent cells.  
 
Clonal expansion of infected cells in vivo 
CD4+ T cells that are actively infected with HIV-1 are rapidly eliminated during anti-
retroviral therapy, but this form of treatment is relatively ineffective in selecting against 
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latently infected CD4+ T cells, which have an estimated half-life of 44 months (Crooks et 
al., 2015; Finzi et al., 1999). Abolishing the latent reservoir is the current hurdle to finding 
a cure for HIV-1 infection. Although we have learned a great deal about the location of 
the latent compartment and its persistence during therapy, it has been difficult to uncover 
whether there are specific genomic features associated with latency (Siliciano and 
Greene, 2011). To further investigate the latent compartment, we used a high throughput 
method that uncovers sites of HIV-1 integration while enumerating clones of expanded T 
cells that bear identical integrations.  
By comparing HIV-1 integration in controllers, untreated and treated progressors, 
including longitudinal samples obtained before and after therapy, we found that 
proliferating clones of infected cells accumulate over time. However, we were unable to 
detect intact, full-length viral sequences in these large, expanded clones. Instead, 
evidence from this study suggests that the reservoir resides primarily in cells that are 
selected against by ART in an integration specific manner, favoring the persistence of 
integrations in intergenic regions and silent genes, and with decay kinetics that argue 
against widespread cell division.  
A number of different investigators have shown that HIV-1 prefers to integrate into 
the introns of highly expressed genes (Craigie and Bushman, 2012). This is true for all of 
the individuals in our study irrespective of their status as controllers or treatment with 
ART. Although the level of intrinsic viremic control has no detectable effect on integration 
site selection, therapy skews the integrated proviral population and selects against genic 
integrations. More specifically, therapy selects against integrations in highly expressed 
genes, when compared to untreated progressors or viremic controllers. Given that ART 
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seems to select for cells that bear silent proviruses, the results suggest that viruses 
integrated into genes are less likely to become latent than those found in intergenic 
regions. Moreover, the data indicate that among the proviruses integrated into genes, 
those that are found in genes expressed at low levels are also more likely to become 
latent. These findings are entirely consistent with in vitro experiments in cell lines showing 
that level of HIV-1 transcription is dependent in part on the status of surrounding 
chromatin (Jordan et al., 2003; Jordan et al., 2001; Sherrill-Mix et al., 2013).    
HIV-1 integration has been studied in multiple cell types, but large libraries of 
integrations sites in primary infected T cells have only recently become available 
(Maldarelli et al., 2014; Wagner et al., 2014). Integration sites obtained from in vitro 
infected cell lines and primary T cells are distinct (Brady et al., 2009; Sherrill-Mix et al., 
2013). Nevertheless, common features of HIV-1 integration have been defined including 
the observation that integration favors Alu repeats (Schroder et al., 2002). This 
association was thought to be dependent on the presence of these repeats in the introns 
of highly expressed genes (Schroder et al., 2002). However, we observed that integration 
preference into highly transcribed genes and into Alu repeats seem to be independently 
important.  
The observation that HIV-1 prefers to integrate in the neighborhood of Alu repeats 
is consistent with the finding that different individuals have been reported to have multiple 
integrations in selected genes (Ikeda et al., 2007; Maldarelli et al., 2014; Schroder et al., 
2002; Wagner et al., 2014).  Our experiments define a group of overlapping hotspots for 
integration that share many of the features of all HIV-1 integrations including preference 
for introns of highly expressed genes and high density of Alu repeats. Viremic progressors 
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showed the highest levels of hotspot integration, possibly because persistent integration 
leads to over-representation of these favored sites, or because persistence of viruses 
integrated in non-hotspot sites are favored and become enriched over time on treatment. 
Alternatively, integration into hotspots might be positively selected by mechanisms that 
remain to be determined. 
Individuals receiving ART show increasing numbers of cells with identical viral 
genomes by SGA analysis suggesting clonal expansion of a subset of cells bearing 
integrated proviruses (Buzon et al., 2014; Chomont et al., 2009; Wagner et al., 2013). 
Two independent groups have recently documented the long-term persistence of 
expanded clones of cells during therapy with ART (Maldarelli et al., 2014; Wagner et al., 
2014). Our analysis confirms and extends these observations by showing that when 
considered as a group, expanded clones are less likely to occur when the provirus is in a 
genic region, and clones that are associated with genes tend to be in genes that are 
expressed at lower levels than single integrations. Thus, proviruses inserted into active 
regions of the genome, which would be more likely to support viral reactivation during T 
cell proliferation, are generally selected against during clonal expansion.  
Why certain integration sites are permissive for clonal expansion is not known but 
finding that expanded clones with integrations occur in cancer related genes led to the 
suggestion that integration into genes that regulate cell division promotes proliferation 
(Wagner et al., 2014). While we also found a higher proportion of integrations in cancer-
related genes as compared to random, this bias was not different from that observed for 
other highly expressed genes favored by HIV-1. Further, we do not see any differential 
bias for integration in cancer related genes in clonally expanded cells compared to single 
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integrations and an overall decrease in the number of integrations in cancer related genes 
during the course of therapy. Since the number and size of clones increases with time on 
therapy, the data indicate that integration into cancer genes is unlikely to be a general 
contributor to the proliferation of infected cells.  
Our data show that ART positively selects for expanded clones and that viremic 
controllers resemble treated progressors in showing a higher proportion of expanded 
clones than untreated viremics. ART selects for clonal integrations irrespective of the 
location in the genome. This is in stark contrast to single, unique integrations, which are 
selected against by therapy. ART specifically favors the survival of single integrations in 
intergenic regions and is biased against genic regions with an overall half-life for single 
integrations of 127 months. The half-life of single integrations is not too dissimilar from 
the current estimate for the latent reservoir, which is believed to decay with a half-life of 
44 months on ART (Finzi et al., 1999).  
 An important outstanding question after the discovery of clonally expanded cells 
with integrated HIV-1 is whether the virus from these large expanded clones of infected 
cells are the major contributor to the latent reservoir (Maldarelli et al., 2014; Wagner et 
al., 2014). Two different independent lines of evidence argue against this idea. First, 
whereas the reservoir appears to decay with time on ART, we find that clonally expanded 
integrations increase with time and do so irrespective of whether they are found in genes 
or intergenic regions. In contrast, single integrations in more active parts of the genome, 
which are more likely to support HIV-1 reactivation, are selected against with time on 
ART. Second, all 75 of the clonally expanded proviruses tested were defective, which is 
in agreement with the 2 examples in the literature (Imamichi et al., 2014; Josefsson et al., 
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2013). Thus, we conclude intact virus is not enriched in clonally expanded infected cells. 
However, we cannot and do not rule out the possibility that a rare clone of cells contains 
an active virus. Nevertheless, the largest expanded clones in ART treated individuals are 
unlikely to be the major source of the rebounding latent reservoir. The data indicate that 
the majority of HIV-1 infected T cells that undergo clonal expansion are able to do so 
because their proviruses are defective and that the replication competent reservoir is 
more likely found in the subset of CD4+ T cells that remain relatively quiescent.  
Identical replication competent viruses found in multiple cells 
The key question arising from the above studies which I have addressed in this 
thesis is how clonal expansion of infected cells contributes to long-term persistence of the 
HIV-1 latent reservoir. Several additional mechanisms have been proposed to account 
for the persistence of this reservoir including low-level viral replication and the long half-
life of latently infected cells.  
Arguments against persistent low-level viral replication include the observation that 
further intensification of anti-retroviral therapy has no measurable effect (Dinoso et al., 
2009; Vallejo et al., 2012). In addition, there is little evidence for viral evolution even after 
prolonged periods of antiretroviral therapy (Joos et al., 2008). In contrast, the idea that 
the reservoir is maintained, at least in part, by the proliferation of latently infected cells is 
supported by the observation of increasing proportions of identical proviral sequences in 
circulating CD4+ T cells (Wagner et al., 2013).  
Archived, proviral integration site analysis, including the study above, provided 
further support for clonal expansion of infected T cells (Cohn et al., 2015; Maldarelli et al., 
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2014; Wagner et al., 2014). In all cases examined, a large proportion of the archived 
integrated proviruses were found to belong to expanded clones of CD4+ T cells that share 
a unique integration site. However, as expected from the observation that the vast 
majority of integrated proviruses are defective (Bruner et al., 2016; Ho et al., 2013), many 
of the proviruses found in clonally expanded T cells are also defective (Cohn et al., 2015). 
The only exception was found in a singular individual suffering from metastatic squamous 
cell carcinoma that showed a large expanded clone of replication competent virus 
(Simonetti et al., 2016). However, the integration site of the provirus in this individual was 
ambiguous and could not be mapped with certainty. One clear caveat of the above 
experiments (Chapter 2) is our inability to purify cells harboring intact latent HIV-1 as 
opposed to cells containing defective viruses. Since the majority of integrated proviruses 
are defective (Ho et al., 2013), it is unsurprising that our experiments were unable to 
capture intact clones.  Thus, the precise contribution of expanded cell clones bearing 
replication competent proviruses to maintaining the latent reservoir is not well defined.  
To examine the diversity of the replication-competent latent reservoir we 
developed a modification of current quantitative viral outgrowth protocols to include a 
qualitative measure of the reservoir of replication-competent proviruses. Q2VOA 
maximizes the yield of limiting dilution cultures to obtain viruses originating from a single 
cell. Consistent with the absence of viral evolution in individuals on suppressive ART, 
Q2VOA revealed that the latent replication-competent viral population is similar between 
time points 4-6 months apart (Evering et al., 2012; Josefsson et al., 2013; Persaud et al., 
2007). This is a relatively short interval in the life of an infected individual, and it will be 
interesting to evaluate the reservoir by Q2VOA over longer time intervals and with various 
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treatment interventions such as antibody therapy or administration of latency reversal 
agents in vivo. 
54% of the viruses emerging in Q2VOA belonged to expanded cell clones bearing 
the same env sequences, and these viruses have a high probability of also being identical 
in the rest of their genomes (Laskey et al., 2016)). The isolation of identical sequences 
from multiple wells on different plates across 2 time-points suggests that these replicating 
viruses do not accumulate significant mutations during 14 days in culture. The lack of 
immunologic pressure under culture conditions may account for this finding. 
While definitive proof that these identical viruses arise by cell division is lacking, 
the identical sequences found in different cells makes it a likely possibility. There are 
several non-mutually exclusive explanations for the prevalence of expanded CD4+ T cell 
clones carrying replication-competent viruses in the latent reservoir. Such cells could be 
clonally expanded as part of normal homeostatic processes, or in response to antigen, or 
as a result of HIV-1 integration into and disruption or activation of genes that regulate cell 
division (Maldarelli et al., 2014; Wagner et al., 2014). Alternatively, identical viral 
sequences could represent a burst of independent viral integration events into unrelated 
CD4+ T cells. Mapping the precise integration sites of the replication-competent 
proviruses or identifying the T cell receptor in cells harboring replication-competent 
proviruses is required to definitively distinguish between viral clones produced by CD4+ 
T cell clonal expansion or bursts of proviral integration. 
Clonally expanded CD4+ T cells with shared proviral integration sites were 
detected in samples of 1-2×106 cells (Cohn et al., 2015; Maldarelli et al., 2014; Wagner 
et al., 2014), which is far fewer cells than the samples assayed in Q2VOA. Only the largest 
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of these previously described expanded cell clones were amenable to further 
characterization, and all 75 proviruses that were examined molecularly showed gross 
defects that rendered them replication incompetent (Cohn et al., 2015). The finding that 
large proviral clones are typically defective is entirely consistent with the observation that 
proviral clone size is inversely related to the probability of reactivation. The larger the 
archival proviral clone, the less likely it was to be represented in the replication-competent 
latent reservoir. This observation is also in agreement with the finding that most clonally 
expanded proviruses integrated into CD4+ T cells are defective (Bruner et al., 2016; Cohn 
et al., 2015; Eriksson et al., 2013; Ho et al., 2013). 
In conclusion, we find clones of replication-competent viruses in the latent 
reservoir. The viral sequences of these clones show limited overlap with archived proviral 
sequences in primary CD4+ T cells, suggesting that the two compartments may be under 
different types of selective pressure in vivo. Finally, if the reservoir is maintained by CD4+ 
T cell division, it may facilitate immunotherapy directed efforts for HIV-1 cure because T 
cell activation is thought to be associated with expression of HIV-1 antigens (Halper-
Stromberg et al., 2014).  
 
Single cell characterization of recently reactivated latent cells 
Identification of clones of replication competent viruses in the latent reservoir 
raised the question whether these clones arise from division of infected cells or a 
homogenous viral burst with independent integration events. Additionally, though we and 
others made significant progress characterizing replication competent viruses, the field 
had yet to achieve latent cell isolation for phenotypic and functional characterization. We 
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set about to devise a strategy that would allow for the isolation and characterization of 
these rare CD4+ T cells from stably treated HIV-1 infected donors. We were guided by a 
method developed for the mouse to identify rare antigen binding cells (Pape et al., 2011), 
which allowed investigators to enrich low-frequency phycoerithrin (PE)-specific B cells 
from naïve mice. We adapted this strategy to capture rare reactivated ex vivo latent CD4+ 
T cells by combining in vitro latency reactivation with antibody-mediated enrichment of 
cells expressing surface viral Envelope in an assay we call Latency Capture (LURE). 
These cells are present in the average individual at low frequency, ranging from 0.1-10 
cells per million peripheral CD4+ T cells. Whether this frequency is higher in tissues such 
as lymph nodes, is a current and ongoing focus of investigation by our group and others. 
LURE allowed us to profile individual reactivated latent cells by single cell RNA 
sequencing. We compared the transcriptome of reactivated LURE cells to uninfected, 
activated cells from the same culture. Although the cells came from the same donors, 
were treated in vitro with the same activation stimulus and processed identically, unbiased 
clustering distinguished the majority of LURE cells from uninfected cells. Some of the 
differences in gene expression between the LURE group and control were large in 
magnitude – 28 genes had greater than 500-fold differential expression in LURE cells 
compared to the controls. We examined our gene list for enrichment using the Gene 
Ontology database and identified a number of enriched pathways of interest. LURE and
control cells show significant differences in the expression of genes that regulate 
transcription. In the list containing the most significantly differently expressed genes, we 
found that expression of 13 transcription factors greatly differed between LURE cells and 
control cells. Unsurprisingly, differential expression of transcription factors resulted in 
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differential expression of many downstream gene pathways. Notably, of the top 10 
significantly enriched pathways, eight were related to immune system function, 
suggesting that response to immune threats are differently regulated in LURE and control 
cells. Control cells express higher levels of interferon responsive genes and genes 
responsible for viral control, implying that they have a heightened response to viral 
infection compared to LURE cells. This difference could be due to either 1) inherent 
differences in LURE and control cells, such as the differential ability of specific T cell 
subsets to respond to pathogens, or 2) since the major certain difference between LURE 
and control cells is the presence of an actively transcribing provirus and consequently 
cytosolic HIV-1 RNA, perhaps this difference in gene expression is simply due to the cells’ 
ability to sense proviral transcription. Additional experiments are ongoing to test the 
response of a latent cell to initial proviral transcription events. However, evidence of 
transcriptional changes upon reactivation from latency suggest that genes encoding 
proteasomes, histone deacetylases, and many transcription factors change in a time-
dependent manner upon entry to the lytic viral lifecycle (Krishnan and Zeichner, 2004), 
suggesting that the cell likely senses early viral transcription after prolonged 
quiescence. Regardless of the mechanism, reactivated latent cells seem to harbor a gene 
expression program that is less responsive to stimuli associated with viral infection than 
control cells obtained from the same cultures. We conclude that the transcriptional profile 
in reactivated latent cells differs from control cells in a number of significant ways, many 
of which are implicated in suppression of immune function.  
We characterized the transcriptome of 85 single reactivated latent cells from the 
blood of three ART suppressed donors with different sized reservoirs. As expected, our 
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ability to isolate latent cells depends, in part, on the number of cells sensitive to 
reactivation in vitro. Due to the relative resistance of some latent cells to reactivation 
(Bruner et al., 2016; Ho et al., 2013) LURE mirrors the viral outgrowth assay and is unable 
to capture the entirety of the latent reservoir. LURE purification of reactivated latent cells 
requires proviral activation to induce Env protein expression on the cell surface.  
Therefore, LURE captures a subset of latent cells with proviruses that can be reactivated 
in a single round of potent T cell stimulation (Bruner et al., 2016; Ho et al., 2013). Some 
reactivated latent cells are certainly lost during the multiple processing stages involved in 
the LURE protocol. Thus, the cells captured by LURE represent a fraction of the 
circulating latent reservoir that is closely related to and overlapping with the latent cells 
that emerge in traditional viral outgrowth assays. Our analysis is also limited to a single 
reactivation agent, PHA. PHA is a lectin that signals through the TCR to induce global T 
cell activation and simultaneously induces viruses out of latency (Laird et al., 2013). Many 
other reagents, used alone or in combination, can also be used to reactivate latent viruses 
(Laird et al., 2015), and will be important to test with LURE in future studies. Our analysis 
is limited to circulating CD4+ T cells that express Env proteins on the cell surface that are 
recognized by our antibody cocktail. We chose a combination of 3 broadly neutralizing 
antibodies, which together cover almost 90% of known circulating strains of HIV-1 
envelope. However, for individuals whose virus is resistant to these antibodies, alternative 
cocktails of antibodies can be used to isolate cells harboring escaped viruses. Our 
analysis is limited to 3 individuals who were chosen based on sample availability and a 
range of reservoir sizes. Examination of additional individuals and methods of latent cell 
reactivation may reveal additional and or different genes and pathways involved in 
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maintaining latency. Finally, further experiments will be required to determine whether 
tissue resident latent cells have a similar gene program upon reactivation.  
T cell division in response to antigen or mitogens like PHA and HIV-1 reactivation 
from latency are stimulated by shared metabolic and transcriptional pathways including 
NFκB (Siliciano and Greene, 2011). Once activated, productive HIV-1 infection typically 
leads to CD4+ T cell death by apoptosis or pyroptosis (Doitsh and Greene, 2016). 
However, cell death after latency reactivation in vitro appears to be stochastic with some 
cells being able to divide and survive after strong stimulation (Hosmane et al., 2017).  Our 
finding that latent cells can survive upon cell division in vivo confirms in vitro experiments 
(Hosmane et al., 2017) and is also consistent with the observation that the latent 
compartment contains groups of CD4+ T cells that harbor proviruses with identical Env 
sequences (Hosmane et al., 2017; Lorenzi et al., 2016). Purification of reactivated latent 
cells by LURE and subsequent TCR sequencing provides definitive evidence that these 
cells arise by clonal expansion in vivo.  The data is consistent with the idea that the 
protracted longevity of the latent compartment is due at least in part to cell division (Bui 
et al., 2017; Cohn et al., 2015; Hosmane et al., 2017; Lee et al., 2017; Lorenzi et al., 
2016; Maldarelli et al., 2014; Mullins and Frenkel, 2017; Simonetti et al., 2016; Wagner 
et al., 2014). Finally, because the reservoir is stable over time (Crooks et al., 2015; 
Siliciano et al., 2003), the finding that latent cells divide implies that they are also dying 
at similar rate, and that the reservoir is a dynamic compartment.  
Antibody binding to Env expressing cells in vivo leads to their accelerated 
clearance (Horwitz et al., 2017; Lu et al., 2016). Should latent cells undergoing clonal 
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expansion in vivo also express viral proteins, they too could be targeted for clearance by 
HIV-1 specific cytotoxic T cells, NK cells or by antibody dependent cellular cytotoxicity. 
How does a subset of latent cells divide and still survive despite expression of HIV-
1? Our single cell transcriptomic analysis of purified primary CD4+ T cells demonstrates 
that reactivated latent cells can express a distinct transcriptional program that includes 
muted responses to type I interferon and factors such as MiR-155 and PRDM1 that can 
suppress HIV-1 transcription (de Masson et al., 2014; Kaczmarek Michaels et al., 2015; 
Ruelas et al., 2015). We speculate that active HIV-1 suppression during CD4+ T cell 
division could be one of the mechanisms that maintains the latent reservoir. Further 
studies will be required to determine whether interference with these cellular safeguards 
could contribute to accelerating latent HIV-1 clearance.  
 
Looking forward 
 Though we have made significant progress understanding the nature of the HIV-1 
latent reservoir, there remain many fundamental unanswered questions relating to the 
persistence of HIV-1 in vivo. I am hopeful that many of these will be answered in the future 
and will have important impacts on therapeutic modalities. Looking forward, I want to 
address five major questions, outlined briefly below: 
1. Reactivation – Advances in reservoir assays like Q2VOA, TILDA, and LURE have 
increased our understanding of the reservoir, yet we rely on the use of known 
latency reversing agents to reactivate latent viruses hidden in CD4+ cells. Despite 
full T cell activation, some viruses do not reactivate (Hosmane et al., 2017). This 
is thought to be due to the stochastic nature of latency reversal, but that hypothesis 
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has yet to be proven. Indeed, we know very little about the way cells reactivate in 
vitro and even less about how they reactivate in vivo. To study reactivation, we 
need more reliable latency models and better assays to measure replication 
competent virus. Large, often unattainable, numbers of patient derived cells are 
required to study ex vivo latency and changes in the reservoir size are hard to 
measure with current methods. Since a large fraction of the latent reservoir is 
clonal in nature (Chapter 4), one insight into reactivation in vivo may lie in our ability 
to determine TCR specificity of the T cell clones harboring replication competent 
latent virus. 
2. TCR specificity – naïve CD4+ T cells each have a unique receptor expressed on 
their surface which is responsible for interacting with specific peptide loaded MHC-
class II. Upon recognition of cognate antigen presented by antigen presenting 
cells, naïve CD4+ T cells undergo robust clonal expansion to aid in the resolution 
of the immune response. We observe clones of CD4+ T cells harboring identical 
intact virus, indicating that upon infection, the latent cells have since divided. Since 
the latent reservoir exists in all individuals, has a long half-life, and is seemingly a 
dynamic compartment, uncovering the specificity of the T cell receptor in latent 
cells may help in our understanding of the maintenance of this reservoir of cells.  
3. Genes controlling latency – While the latent compartment seems to be dynamic, 
it defies dogma because cell activation, division, and latency reactivation are 
controlled, in part, by the same transcription factors. Furthermore, it is thought that 
latency reactivation leads immediately to cell death due to the cytopathic effects of 
viral infection. Thus, investigation into genes responsible for maintenance of 
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latency during division will be fundamental to our understanding of persistence in 
vivo. Experiments performed on LURE cells have allowed the curation of a 
preliminary list of genes which could play a role in persistence, but further 
experiments to elucidate their function are required. Additionally, because LURE 
requires cell activation for purification, developing strategies to isolate and 
characterize gene expression in unstimulated latent cells directly ex vivo remains 
a top priority. 
4. Integration sites – To date, it has been impossible to link integration site with 
replication-competent intact virus. Using LURE, there is great potential to discover 
integration sites that correspond to intact virus. Our data suggests that integrations 
in highly expressed genes will be unlikely candidates for long term persistence, but 
this important hypothesis remains to be definitely demonstrated. 
5. Contribution of tissue resident cells – Finally, almost all experiments 
characterizing the latent reservoir in patients are performed on PBMCs from blood. 
However, T cells in the blood account for only a small fraction of the total CD4+ T 
cells in the body (Farber et al., 2014). Due to their non-invasive harvest compared 
with other tissues, they have been the primary focus of HIV-1 research. Tissue 
resident CD4+ T cells have become increasingly a focus for HIV-1 cure research 
due to their proximity to the site of infection and the presence of an inducible 
reservoir found in T follicular helper cells isolated from lymph nodes (Perreau et 
al., 2013). Most studies performed on tissue have been using the non-human 
primate model, but recently protocols to harvest human lymph tissue, gut biopsies 
and programs to harvest tissue post mortem are allowing for more robust 
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understanding of the contribution to persistence by tissue. I believe these studies 
are going to dramatically expand the way we think about HIV-1 persistence. 
 
Collectively, the results described in this thesis provide evidence for the contribution of 
proliferating CD4+ T cells to the HIV-1 latent reservoir in ART suppressed patients. The 
data also suggests a mechanism for persistence through division whereby cells harboring 
intact latent virus express genes which may reduce HIV-1 transcription. These data 
illustrate the latent reservoir as dynamic target and therapeutic strategies addressing its 





MATERIALS AND METHODS 
 
Human sample collection 
Human samples were collected after signed informed consent in accordance with 
Institutional Review Board (IRB)-reviewed protocols by all participating institutions. For 
the integration study, participants 1, 2, and 3 were selected from the Seattle HIV 
longitudinal cohort studies at Fred Hutchinson Cancer Research Center. Participants 4, 
8 and 9 were recruited from the University of Cologne and samples were obtained at 
Rockefeller University. Participants 5, 6 and 7 were selected from the Rockefeller 
University HIV-1 antibody therapy clinical trial. Participants 10, 11, 12, and 13 were 
selected from a group of elite controllers that were followed at the Ragon Institute in 
Boston. For the Q2VOA and LURE studies, all individuals were recruited by the 
Rockefeller Hospital and leukapheresis obtained and processed at Rockefeller. 
 Eligible participants were adults aged 18–65 years with HIV-1 infection and 
undetectable plasma HIV-1 RNA levels (<20 copies/ml) while on ART. PBMCs were 
isolated by Ficoll separation and frozen in aliquots. In all cases, HIV-1 infected 
participants on therapy were confirmed to be aviremic at the time of sample collection.  
  
Integration Library  





CD4+ T cell isolation 
CD4+ T cells were isolated from whole PBMC using anti-CD4 microbeads (Miltenyi 
Biotec). The percentage of live cells was determined by flow cytometry based on forward 
and side scatter. Purity of CD4+ T cells was determined by labeling isolated cells with 
anti-human CD3, CD4, CD8, CD19 and HLA-DR and gating on CD3, CD4 double positive 
cells. Isolated cells were used for library construction only if purity was >75%.  
 
DNA preparation 
0.2-2 million CD4+ T cells from HIV-1 infected individuals were lysed in Proteinase 
K buffer (100mM Tris [pH8], 0.2% SDS, 200mM NaCl, 5mM EDTA) and 5-10uL of 
20mg/mL Proteinase K. Genomic DNA was extracted by phenol chloroform and 
fragmented by sonication (Covartis) to yield a 300-1000bp distribution of DNA fragments. 
DNA was blunted by End-It DNA Repair Kit (Epicenter), purified, then adenosine-tailed 
by Klenow fragment 3 à 5’ exo- (NEB) and purified. Fragments were ligated to 200pmol 
of annealed linkers (Table S2). Virus sequences were eliminated by digestion with BglII 
(NEB) and fragments were purified.  
 
Integration site amplification  
Semi-nested ligation-mediated PCR was performed on linker-ligated DNA. Linkers 
made by annealing two oligos: GCAGCGGATAACAATTTCACACAGGACGTACTGTGG 
CGCGCCT and 5’ phosphorylated, 3’ dideoxycytosine GGCGCGCCACAGTACTTGAC 
 
 101 
TGAGCTTTA. All PCRs were performed using the Phusion Polymerase system 
(Thermo). DNA was divided into 700ng aliquots and subjected to single-primer PCR with 
biotinylated LTR1 (5’ bio: CTTAAGCCTCAATAAAGCTTGCCTTGAG) [1x(98C-1min) 12x 
(98C-15s, 62C-30s, 72C-30s) 1x(72C-5min)]. Each reaction was spiked with pLinker 
(GCAGCGGATAACAATTTCACACAGGAC) and subjected to additional cycles of PCR 
[1x(98C-1min) 25x(98C-15s, 62C-30s, 72C-30s) 1x(72C-5min)]. Products of 300-1000bp 
were isolated by agarose gel electrophoresis and magnetic streptavidin bead purification. 
Semi-nested PCR was performed on the magnetic beads first with a single primer LTR2 
(AGACCCTTTTAGTCAGTGTGGAAAATC) [1x(98C-1min) 12x(98C-15s, 62C-30s, 72C-
30s) 1x(72C-5min)] followed by spiking in pLinker and additional cycles [1x(98C-1min) 
25x(98C-15s, 62C-30s, 72C-30s) 1x(72C-5min)] (Table S2). Products of 300-1000bp 
were isolated by agarose gel electrophoresis.  
 
Paired-end library preparation 
Linkers were digested by AscI such that a 6-nucleotide barcode (CGCGCC) was 
left on the DNA fragments, indicating linker-dependent amplification. Fragments were 
blunted by End-It DNA Repair Kit (Epicenter), purified with AmPure beads (Agencourt) 
and ligated to NextFlex paired-end adapters. Adaptor-ligated fragments were enriched by 
35 cycles of PCR with NextFlex primers [1x(98C-1min) 35x(98C-15s, 66C-30s, 72C-30s) 
1x(72C-5min)] and fragments between 300-1000bp were isolated by gel electrophoresis. 
Three libraries were mixed in equimolar ratios and sequenced by either 150bp paired-
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end sequencing on Illumina MiSeq or 150bp or 100bp paired-end sequencing on an 
Illumina 2500.  
 
Computational Analysis for Integration Site Identification 
Read Alignment 
Paired-end reads were mapped to the HIV-1 sequence (designated as a bait) using 
BLAT (Kent, 2002) with default settings. Reads that were mapped to the virus bait without 
mismatches, were checked for the linker barcode in the paired-end read, then barcode 
sequence was trimmed and the remainder was mapped to the human genome reference 
GRCh37/hg19) with Bowtie (Langmead et al., 2009). Only uniquely mapped reads 
(allowing for to 2 mismatches) were used as defined in the best alignment stratum 
(command line options: -v2 -all -best -strata -m1). Identical reads generated by PCR 
amplification were merged. 
 
Integration determination  
Once the paired-end reads (pair 1 and pair 2) were properly mapped in the bait 
and human genome reference respectively (see above), we determined the integration 
breakpoint by aligning the remaining nucleotide sequence that contained the 3' terminus 
of the HIV-1 LTR to the human genome using BLAT (default settings). Only uniquely 
mapped reads up to 1Kb away from its partner (pair 2) were kept. Adjacent (within 50 
nucleotides) putative integrations sites were merged. Finally, the 5' end of pair 1 and pair 





To detect preferred sites of HIV-1 integration genome-wide, we subjected our data 
set to hot_scan software analysis (Silva et al., 2014), which defines hotspots by scan 
statistics.  Hotspots obtained by hot_scan were defined using different window widths 
(100, 200, 500, 1000, 2000, 5000, 10000, 20000, 50000 and 100000 bp). 
 
Monte Carlo Simulation for virus integration and hotspots 
To assess whether viral integration sites and hotspots are enriched around the 
INT-motif, we conducted a Monte Carlo simulation by shuffling the genomic locations of 
all virus integration sites or hotspot regions 10000 times using bedtools shuffle utility 
(Quinlan and Hall, 2010), and we counted the number of the randomized integrations 
which were 50bp or 1kb from a motif site. Then, we compared the observed number of 
motifs in hotspots with the median number of motifs in the randomized hotspots list. In 
both analysis, we assessed potential enrichments by P-value derived by counting the 
number of times that the number of observed events was equal or higher than the number 
of randomized events divided by N=10000. 
 
Statistical analysis 
All statistical analyses were done using R language.  
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Proportion test is the standard test for the difference between proportions, also 
known as a two-proportion z-test. We used R’s implementation of this via the prop.test() 
function. 
 
Integration library verification 
To verify our integration sequencing strategy, we also constructed two libraries 
from DNA isolated from uninfected individuals. We recovered 13 sequences that mapped 
to integration sites. We subtracted these “integration sites” from all libraries before further 
analysis.  
To test for the saturation of our method, two separate integration libraries were 
constructed from identical samples for three participants. We found that both libraries 
contained the same expanded clonal families, but the majority of single virus integrations 
were unique to each sample of cells used for library construction. Single viral integrations 
found in both libraries were less than 1% of observed viral integrations.   
 
PCR verification   
Genomic DNA isolated as described above was serially diluted and subjected to 
nested-PCR using genomic specific primers and primers LTR1 and LTR2 using HotStart 
Taq Polymerase (Qiagen) [1x(98C-14min) 40x(98C-30s, 55C-30s, 72C-30s) 1x(72C-
5min)]. Products were isolated by gel electrophoresis and sequenced directly. Analysis 
of clones in this manner identified that integration sequencing underestimates the size of 





5’ LTRs from large clones were amplified with nested genomic primers and 
LTR2Rev (Table S2) using Platinum High Fidelity Taq (Invitrogen) or HotStart Taq 
Polymerase (Qiagen) [1x(98C-14min) 40x(98C-30s, 55C-30s, 72C-1min) 1x(72C-5min)]. 
Products were isolated by gel electrophoresis and sequenced directly. 
 
Full Length Virus 
The virus sequencing method was adapted from Ho et al (Ho et al., 2013). Full 
length genomic DNA from infected individuals was isolated as described above and 
serially diluted into PCR tubes. Each well was filled to a final volume of 50µL with PCR 
reaction mixture (Platinum Taq MasterMix, Invitrogen) and primers to amplify virus from 
a specific integration site in the genome using touchdown cycling to increase specificity. 
Then, 2µL aliquots from the first PCR were subjected to nested genomic PCR and 1% 




 Viral outgrowth cultures were performed as previously described (Laird et al., 
2016; van 't Wout et al., 2008). PBMCs from virologically suppressed chronically HIV-
infected individuals on ART were obtained by leukapheresis. Briefly, leukapheresis 
products from each study participant at each time point were processed and PBMCs were 
isolated by density centrifugation on Ficoll (Thermo Scientific). Cryopreserved PBMCs 
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were then used to isolate total CD4+ T lymphocytes using negative selection by magnetic 
beads (Miltenyi). Purified CD4+ T lymphocytes were cultured at 0.3x106 cells per well in 
24-well plates in 1 ml of RPMI 1640 (RPMI; Gibco) supplemented with 10% fetal bovine 
serum (FBS; HyClone, Thermo Scientific), 1% Penicillin/Streptomycin (Gibco), 1 µg/ml 
Phytohemagglutinin (PHA; Life Technologies), and 100 U/ml of IL-2 (Peprotech) at 37°C 
and 5% CO2. Each well also received 1ml of medium containing 2.5x106 irradiated 
heterologous PBMCs. After 24 hours 1.5ml of medium was discarded and 106 CD8+-
depleted lymphoblasts from an HIV-negative donor were added to each well as target 
cells. At day 9, 1 ml of medium was removed and another 106 CD8+ depleted CD4+ T 
lymphoblasts were added to each well. At day 14 the supernatant of each well was tested 
for HIV-1 production using the Lenti-X p24 Rapid Titer Kit (Clontech) according to the 
manufacturer’s instructions.  Under these conditions, using 0.3x106 donor cells, less than 
30% of all cultures were positive for all individuals. 
 
Bulk Cultures 
Bulk cultures were performed as previously described (Caskey et al., 2015). 
Sequence analysis on bulk culture was also performed as previously described (Scheid 





Sequence analysis for Q2VOA 
 The supernatant from p24-positive cultures was extracted using Qiagen MinElute 
Virus Spin kit QIAcube. cDNA was produced using 1:10 diluted RNA with the SuperScript 
III reverse transcriptase (Invitrogen Life Technologies) and the antisense primer env3out 
5’–TTGCTACTTGTGATTGCTCCATGT–3’ followed by RNase H digestion (Invitrogen 
Life Technologies) for 20 minutes at 37 °C. The full gp160 env was amplified from 1:40 
diluted cDNA using envB5out 5’–TAGAGCCCTGGAAGCATCCAGGAAG–3’ and 
envB3out 5’–TTGCTACTTGTGATTGCTCCATGT–3’ in the first round and second round 
nested primers envB5in 5’–TTAGGCATCTCCTATGGCAGGAAGAAG–3’ and envB3in 
5’– GTCTCGAGATACTGCTCCCACCC-3’.  
PCRs were performed using a High Fidelity Platinum Taq (Invitrogen) at 94°C, 2 
min; (94°C, 15 sec; 55°C 30 sec; 68°C, 4 min) × 35; 68°C, 15 min. Second round nested 
PCR was performed using 1 µl of PCR1 product as template and High Fidelity Platinum 
Taq at 94°C, 2 min; (94°C, 15 sec; 57°C 30 sec; 68°C, 4 min) × 45; 68°C, 15 min. PCR2 
products were checked using 1% 96-well E-Gels (Invitrogen). PCR bands with expected 
HIV envelope size were quantified and subjected to library preparation using the Illumina 
Nextera DNA Sample Preparation Kit (Illumina) as described (Kryazhimskiy et al., 2014). 
Briefly, 10 ng of DNA per band were subjected to tagmentation, ligated to barcoded 
sequencing adapters using the Illumina Nextera Index Kit and then purified using AmPure 
Beads XP (Agencourt). 96 different purified samples were pooled into one library and 
then subjected to paired-end sequencing using Illumina MiSeq Nano 300 (Illumina) cycle 
kits at a concentration of 15 pM.  
Sequence adapters were removed using Cutadapt v1.8.3. Read assembly for each  
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virus was performed in three steps. First, de novo assembly was performed using Spades 
v3.6.1 to yield long contig files. Contigs longer than 255bp were subsequently aligned to 
an HIV envelope reference sequence and a consensus sequence was generated using 
Geneious 8. Finally, reads were re-aligned to the consensus sequence to close gaps and 
a final read consensus was generated for each sequence. Sequences with double peaks 
(cutoff consensus identity for any residue <75%), stop codons, or shorter than the 
expected envelope size were omitted from downstream analyses.  
 
Proviral Single Genome Amplification  
 DNA from 1-10×106 CD4+ cells from HIV-1-infected individuals was prepared as 
previously described (Klein et al., 2011). Briefly, cells were collected after magnetic 
isolation and lysed in Proteinase K buffer (100 mM Tris [pH 8], 0.2% SDS, 200 mM NaCl, 
5 mM EDTA) and 20mg/ml of Proteinase K at 56°C for 12 hours. Genomic DNA was 
extracted by phenol chloroform precipitation. Aliquots of the resulting DNA were diluted 
and used as template for full-length gp160 PCRs. All PCRs were performed using a High 
Fidelity Platinum Taq (Invitrogen). The first PCR at 94°C, 2 min; (94°C, 15 sec; 58.5°C 
30 sec; 68°C, 4 min) × 35; 68°C, 15 min. Second round nested PCR was then performed 
using 1 µl of PCR1 product as template and High Fidelity Platinum Taq at 94°C, 2 min; 
(94°C, 15 sec; 61°C 30 sec; 68°C, 4 min) × 45; 68°C, 15 min. PCR2 products were 
checked using 1% 96-well E-Gels (Invitrogen). Bands with expected size of the HIV-1 
envelope obtained from diluted DNA samples that showed an amplification efficiency of 
less than 30% were subjected to library preparation and sequencing using the Illumina 
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platform as described above. Hypermutants, sequences with double peaks (cutoff 
consensus identity for any residue <75%), stop codons, or shorter than the expected 
envelope size were omitted from downstream analyses.  
 
Genealogical Sorting Index  
The Genealogical Sorting Index (GSI) (Cummings et al., 2008) was used to 
calculate the degree of phylogenetic association of the env gene sequences. Phylogenies 
were inferred using PhyML version 3.0 (Guindon et al., 2010). Multiple bifurcations with 
intervening zero-length branches were collapsed to polytomies using the di2multi method 
implemented in the ape package for R (Paradis et al., 2004). These phylogram topologies 
were used to calculate the gsi values and p-values were determined using 10,000 
replicate permutations (Cummings et al., 2008). 
 
Computational Analyses 
Bayesian inference was implemented in Stan (Carpenter et al., 2016) to jointly 
estimate the frequency of integrated proviruses and their reactivation probability. Data 
from proviral DNA sequencing and viral outgrowth assays were combined across multiple 
visits, incorporating a prior probability for the gradual decay of the reservoir (Crooks et 
al., 2015; Siliciano et al., 2003). We assumed a weakly informative prior for the frequency 
of integrated provirus and a uniform prior for the probability of reactivation. Parameters 
were estimated individually for viruses with identical sequences observed at least three 
times across both visits (large clones), while sequences observed less frequently were 
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grouped together (small clones). The observed relationship between clone frequency and 
reactivation probability also holds in simpler models incorporating data from single visits 




Cells were cultured at 2x106/mL in R10 (RPMI supplemented with 10% heat 
inactivated FCS, 10mM HEPES, 100U/mL PenStrep), and 25% volume conditioned 
media. Conditioned media was made by culturing healthy PBMCs in R10 with PHA and 
IL-2 for 2 days, followed by a wash and 5 days in culture with IL-2 alone. The conditioned 
media was then collected and frozen at -80C until use. 100U/mL IL-2 (Peprotech), 1ug/mL 
PHA (Sigma), 10uM Z-VAD-FKM (R&D), 10uM Ritonavir, 10uM Dolutegravir, 10uM 
Emtricitabine, 5uM Tenofovir, and 10uM Maraviroc (all Selleckchem) were added to the 
media. 36h later, cells were labeled with 5ug/mL each of biotinylated 3BNC117, 10-1074, 
PG16, followed by Streptavidin PE (1:500, BD) and anti-PE magnetic beads (Miltenyi 
Biotech). Cells were then passed over a magnetic column and bound cells were eluted 
for downstream analysis. For FACS sorting, cells were labeled with the following 
antibodies, all Biolegend: CD1c (cat. no. 331510), CD3 (cat. no. 300430), CD4 (cat. no. 
317444), CD8 (cat. no. 344726), CD14 (cat. no. 301812), CD20 (cat. no. 302318), CD32a 




Gag bulk qPCR 
RNA was extracted from equivalent numbers of cells irrespective of enrichment. 
Gag qPCR was performed using RNA-to-CT one-step RT-PCR mix (ThermoFisher) and 
previously described primers (Palmer et al., 2003).  
 
Single Cell sorting 
All sorts were performed on BD FACS Aria into 96-well plates containing guanidine 
thiocyanate buffer (Qiagen) supplemented with 1% β-mercaptoethanol. Plates were 
immediately frozen on dry ice and transferred to long-term storage at -80C. LURE cells 
were gated on live, CD1c, CD8, CD14, CD20, and CD56 negative, CD3 positive and 
sorted based on Env staining. Control cells were gated on live, CD1c, CD8, CD14, CD20, 
and CD56 negative and sorted CD3 positive cells. 
 
Single Cell gag qPCR and ENV PCR 
Nucleic acids were isolated by SPRI bead cleanup as described (Tas et al., 2016). 
RNA was reverse-transcribed into cDNA using an oligo(dT) primer. Gag qPCR was 
performed on one-fifth of the cDNA (Palmer et al., 2003). Gag+Env+ cells were selected 
based on the presence of cell-associated gag RNA measured by qPCR. Control cells 
were assayed for gag RNA and none was detected. Nested Env PCR was performed on 




YU2 infection and sorting 
CD4+ T cells were activated and infected with YU2 and labeled as previously 
described (Lu et al., 2016). CD4lo, Envelope positive cells were sorted.  
 
Single Cell RNASeq 
RNASeq libraries were constructed based on Trombetta et al. (Trombetta et al., 
2014) using primers from Islam et al. (Islam et al., 2014) Briefly, RNA was converted to 
full-length cDNA using oligo(dT) priming (Bio-AATGATACGGCGACC 
ACCGATCGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT) and SMART template switching 
technology (all RNA oligo: Bio-AAUGAUACGGCGACCACCGAUNNNNNGGG) followed 
by 24 cycles of PCR preamplification of cDNA (primer Bio-
GAATGATACGGCGACCACCGAT). We used the amplified cDNA to construct standard 
Illumina sequencing libraries Nextera XT library preparation kit. Samples were 
sequenced by Illumina NextSeq.  
 
RNASeq Analysis 
The quality of the RNASeq libraries was evaluated using the fastQC1 (Anders et 
al., 2015). We used STAR (2.4.1d) (Dobin et al., 2013) aligner to map the raw paired-end 
reads to the reference genome GRCh37/hg19. The gene-level counts were obtained 
using HTSEQ (Anders et al., 2015). We performed a saturation analysis to detect the 
number of detected genes and filtered out the outlier cells as in Gaublomme et al 
(Gaublomme et al., 2015). Briefly, we excluded cells with number of aligned reads 
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<25,000 and percentage of identified genes <20% of the group maximum. Normalized 
expression values were calculated using the scran package (Lun et al., 2016). Heatmaps 
and dotplots were generated in R. The gene counts were used to infer the differentially 
expressed genes (DEG) in the data by MAST (v1.2.1) (Finak et al., 2015). 
 
HIV Splice variant analysis 
We recovered the reads which failed to map to the human genome and mapped 
these reads to annotated junctions between HIV splice donors and acceptors to 
reconstruct the splice variants present in the scRNASeq data.  
 
HIV reads alignment and reconstruction 
We carried out HIV assembly analysis on the all reads which failed to map to the 
human genome by the IVA de novo assembler (v1.0.7) (Hunt et al., 2015).  
 
TCR identification  
TraceR (Stubbington et al., 2016) was used to reconstruct full-length, paired T cell 
receptor (TCR) sequences. 
TCR sequences unable to be recovered from RNASeq reads were amplified as 





We used the Seurat package (v1.4.0.16) to identify variable genes, principal 
components (PCs), clusters and gene markers as described (Satija et al., 2015). Briefly, 
the software identifies highly variably expressed genes using a normalized z-score, 
performs linear dimensional reduction (PCA) on the filtered genes, obtains additional 
transcriptome PCA loading genes using projection of these principal components to the 
entire dataset, determines groups by density clustering of the t-SNE significant principal 
component scores and performs gene marker discovery. We also used the Improved 
Stochastic Ranking Evolution Strategy algorithm (Runarsson and Yao, 2005) 
implemented by NLopt, to find the optimal set of PCs and parameters, and to find the 
optimal set of clusters that best correlate with each group of cells.  
 
Single Cell Consensus Clustering  
Single-Cell Consensus Clustering (SC3) tool (Kiselev et al., 2017) (default 
settings) was used for unsupervised clustering of single cells in this study.  SC3 
consistently integrates different clustering solutions through a consensus approach and 
identifies marker genes which are highly expressed in only one of the clusters and are 
able to distinguish it from all the remaining ones. 
We have tested combinations of clustering settings (k=2, 3 and 4) and used a 
quantitative measure of the diagonality of the consensus matrix to select the k in which 
the measure is closest to 1 (k=3). We then used SC3 (AUROC>0.6 and FDR < 0.1) to 
identify marker genes which are highly expressed in only one of the clusters and are able 
to distinguish it from all the remaining clusters. 
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Data availability  
The data reported in this thesis is archived at the following databases:  
Data from Chapter 2 are accessible via NCBI SRA using the accession number 
SRP045822.  
Data from Chapter 3 have been deposited in the GenBank database using accession 
numbers KY113379–KY114054.  
Data from Chapter 4 are available via multiple databases: Single cell RNASeq data is 
available at NCBI GEO (GSM2801437); Envelope sequences are available in the 
Genebank database (MG196359 - MG196639); TCR sequences are available in the 







240 genes which overlap between principal components analysis and differential 
expression analysis (LURE vs control). Positive fold change indicates genes highly 
expressed in LURE cells. Negative fold change indicates genes highly expressed in 
control cells.  
Gene Name p-value Fold Change 
PRDM1 1.28E-06 1365.04 
MAF 0.000931106 1222.00 
CCL3 3.31E-05 795.63 
GPR171 3.09E-10 741.65 
ZBED2 0.000178928 729.34 
SRGN 8.80E-07 660.79 
IRF4 1.35E-10 626.10 
RGS1 0.001195892 614.30 
LINC-PINT_dup2 7.66E-05 485.05 
MIR155HG 1.32E-06 368.48 
MTDH 1.45E-05 350.12 
IL21-AS1 4.19E-14 337.92 
ATP1B3 0.000131055 298.96 
PSMA7 0.006644358 290.93 
RDH10 0.000686327 282.16 
CD96 0.001107027 279.72 
TNFAIP8 8.53E-07 270.69 
STX11 0.000925105 267.24 
RAB27A 1.04E-05 266.35 
RNR1 0.001522231 258.26 
IQCG 5.85E-05 257.99 
STOM 2.16E-06 256.51 
MT2A 0.000596151 254.52 
EXOC2 0.000199389 254.23 
VMP1 1.34E-05 249.53 
AKAP13 1.27E-08 237.65 
PIK3CG 1.59E-09 190.23 
SAE1 0.001266734 189.14 
GSTP1 4.41E-06 187.08 
MCOLN2 5.23E-08 185.02 
OAZ1 0.004028392 183.23 
IKZF3 1.09E-06 179.89 
TMEM173 0.001445032 170.19 
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PSMB3 6.11E-05 166.34 
PSMD12 0.000531619 162.36 
BATF3 3.28E-09 158.94 
NDUFAB1 0.000522233 156.25 
CCT3 2.98E-05 149.31 
CTSB 6.46E-05 148.74 
GPR183 0.000444313 145.95 
NDUFS5 1.65E-06 142.89 
PEBP1 0.009299749 142.84 
HUWE1 0.000364271 139.87 
TIGIT 1.44E-06 137.58 
BST2 0.0070902 134.12 
INPP4B 3.81E-10 129.73 
ST8SIA4 0.000119258 129.15 
CD53 0.001193214 126.33 
SMARCA2 9.33E-07 125.78 
ARAP2 0.008208236 123.72 
IL12RB2 1.40E-06 108.10 
NDUFA8 0.000864071 104.91 
GTF2A2 0.001514079 103.66 
CRIM1 1.45E-07 103.03 
TMBIM6 0.000683334 101.61 
C4orf3 0.000352459 99.83 
PPP3CA 0.001166999 98.07 
RNASEH2C 0.004424494 97.84 
HLA-DQB1 7.66E-09 96.91 
SUSD6 0.009646603 96.59 
TRPS1 7.90E-08 96.56 
NIT2 0.000808645 93.11 
CREM 6.46E-05 93.04 
COPS5 0.002519311 92.93 
SDF4 0.008562895 92.31 
ACTA2 1.56E-09 91.12 
RAPGEF2 1.17E-05 90.23 
ARID5B 4.50E-05 90.16 
TPM4 0.003295339 88.84 
CYTOR 0.006228062 87.10 
ZEB2 9.95E-05 86.50 
MT1X 0.001493762 80.13 
NDUFA11 0.00711934 78.81 
RANBP2 0.002914352 78.40 
DNTTIP2 0.002506043 78.13 
FABP5 2.40E-06 77.89 
FBXW5 0.002510012 77.80 
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COX5B 1.16E-05 76.66 
HLA-DRB1 6.53E-09 74.58 
RORA 3.69E-05 74.14 
ZBTB38 2.53E-05 73.86 
RNF19A 0.001374051 70.37 
PRDX6 0.000426547 64.34 
C17orf62 0.00039074 60.27 
NME1 0.00251826 60.08 
SEC63 0.009747048 57.31 
TNFRSF9 0.000166316 56.89 
MSC 5.66E-07 55.70 
ADRM1 0.00104375 54.83 
HLA-DPA1 1.09E-06 53.40 
KRT10 0.001280249 50.73 
NAA38 0.004901974 50.16 
CD226 8.53E-07 49.78 
S100A10 5.81E-09 48.84 
SRI 0.000196042 47.48 
DGKH 7.22E-05 41.28 
IPCEF1 0.000188963 40.85 
NDUFB6 0.002733726 40.01 
TOX 7.04E-11 39.94 
C12orf57 0.00440838 39.51 
MIR4435-2HG 0.000257797 38.76 
SFT2D1 0.000142357 33.76 
NAMPT 6.13E-08 32.98 
PSMD4 0.002610897 32.64 
PSMD11 4.25E-06 32.52 
UBE2D1 0.00481846 32.44 
COA6 9.25E-05 30.95 
APOL1 0.001017343 30.69 
RBPJ 5.18E-05 27.76 
UBAC2 0.002421166 26.68 
STRIP2 2.87E-07 25.48 
BTF3 0.000129221 22.04 
SMIM15 0.00130664 18.33 
AHR 2.76E-07 17.54 
SEC61G 0.008242902 16.00 
MLEC 0.002695913 15.38 
CASK 0.000342703 12.29 
EVI5 0.00279202 11.74 
ELL2 0.000343087 10.73 
TMEM70 7.40E-07 10.36 
GTF3C6 0.002807797 9.43 
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PSMD7 0.007641893 9.10 
OSTF1 0.000316277 6.58 
OIP5 0.001004668 4.76 
PCMT1 0.000785253 1.78 
MIR6723 0.001548566 1.71 
F2R 7.07E-06 1.04 
YWHAQ 0.008488231 -0.68 
CHMP1B 0.000680176 -0.71 
HIPK2 0.004757124 -1.63 
YWHAB 0.004221649 -2.05 
TBK1 0.000146177 -7.71 
CD2BP2 0.004625936 -7.80 
PRKCQ 0.0022731 -7.91 
TIMM17A 0.007815617 -11.81 
SH2D1A 0.000329061 -13.34 
CASP4 0.001320572 -13.40 
EED 0.000371361 -15.30 
TNFRSF18 0.001768085 -16.19 
TRIB2 0.00462457 -16.20 
DCXR 0.004391609 -22.11 
NDRG3 0.008790155 -24.33 
GALM 5.04E-06 -25.53 
LIMS1 1.88E-06 -26.21 
NDUFA6 0.008180147 -26.40 
CTLA4 0.000619876 -26.71 
RDX 9.90E-05 -29.57 
PLAC8 1.65E-07 -30.64 
FAM162A 0.00079396 -30.89 
ETV6 0.00658202 -36.00 
CST7 0.008462729 -36.16 
RASA2 0.003317739 -36.22 
NDUFA4 0.000102627 -36.91 
CDK2AP2 0.002775209 -37.34 
MMD 0.00375033 -37.66 
PRKCA 0.008697013 -41.96 
MAGOH 0.005135903 -42.15 
PDIA6 0.000218341 -42.94 
LPAR6 0.009600017 -43.81 
SOCS3 0.001998066 -50.06 
SLA 0.006174637 -50.88 
LAG3 0.009802407 -53.23 
POMP 0.008302933 -54.65 
MAL 0.000442452 -56.70 
CCL5 5.19E-07 -56.82 
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BBX 0.008655036 -59.35 
COX5A 0.002052359 -61.34 
DNAJB11 0.002703867 -61.95 
ARPP19 0.000129775 -62.31 
STYX 0.002902084 -63.07 
ITGB1BP1 0.009295115 -65.51 
AKR1B1 0.000496086 -66.57 
GHITM 0.007645077 -78.61 
PSMD1 0.004990284 -78.67 
HERPUD2 0.00202364 -81.67 
S100A4 0.00093742 -83.69 
PSMC1 0.003123379 -87.12 
MAP3K8 0.002806797 -90.45 
CNN2 0.000413875 -90.68 
CASP10 0.000124689 -94.16 
GBP4 0.003172026 -96.15 
UQCRC2 0.009705553 -97.62 
RABAC1 0.003594757 -99.15 
ARL6IP4 0.00327542 -112.93 
G3BP2 0.00345263 -117.79 
EMP3 0.001016469 -119.19 
RAP1A 0.005492263 -122.49 
GIMAP7 0.000167305 -124.57 
IFIT3 0.000847454 -127.10 
EIF3M 0.002866585 -134.66 
NFKBIZ 0.008591639 -135.56 
CTNNB1 0.002914301 -139.35 
SEMA4D 0.003775067 -141.50 
BCCIP 0.003608674 -142.45 
TMED10 0.000716056 -144.23 
HSPA9 0.006574652 -148.39 
VCP 5.15E-05 -155.23 
TALDO1 0.001231597 -157.09 
UBE2L6 0.00729835 -159.37 
ARGLU1 0.001840139 -161.74 
SCD 0.004039508 -163.27 
SYNE2 0.001555763 -166.54 
ISG20 0.000162219 -176.05 
SKIL 3.61E-06 -184.26 
PSMB6 0.004321897 -184.26 
PIK3CD 0.003799058 -191.10 
IRF1 0.001345965 -208.58 
SH3KBP1 0.007169478 -211.86 
S100A11 0.003714074 -219.94 
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NOP58 0.000654669 -226.08 
IFI6 4.76E-06 -263.15 
TPI1 0.003160064 -263.92 
PSMA6 0.00232043 -269.09 
SERINC5 0.000246139 -278.29 
LGALS1 0.000160923 -280.41 
IL2RA 0.003065813 -295.42 
EZR 0.00394443 -330.43 
RSAD2 0.000159317 -338.85 
DDIT4 0.001158105 -339.04 
RPS9 0.00073819 -344.22 
IFI44L 0.000330539 -347.29 
HNRNPA2B1 0.009409872 -373.48 
STAT1 0.006105408 -413.06 
CCND2 0.002017967 -413.66 
XAF1 5.09E-06 -415.07 
UBE2B 0.000596287 -456.00 
ARPC1B 3.22E-05 -485.98 
GBP5 1.08E-06 -488.05 
CORO1A 0.000552011 -490.77 
PGK1 0.005921922 -564.96 
PIM2 5.88E-14 -580.10 
PARP14 0.006204162 -671.70 
IL32 0.000683834 -709.68 
LTB 1.26E-11 -732.60 
PARP9 4.37E-07 -794.81 
YWHAZ 0.008959673 -885.59 
DTX3L 0.0053721 -891.16 
APOL2 1.07E-06 -1104.25 
PPP1CB 0.004961738 -1154.06 
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